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Severe influenza infection represents a leading cause of global morbidity and mortal-
ity. Although influenza is primarily considered a viral infection that results in pathology 
limited to the respiratory system, clinical reports suggest that influenza infection is 
frequently associated with a number of clinical syndromes that involve organ systems 
outside the respiratory tract. A comprehensive MEDLINE literature review of articles 
pertaining to extra- pulmonary complications of influenza infection, using organ- 
specific search terms, yielded 218 articles including case reports, epidemiologic inves-
tigations, and autopsy studies that were reviewed to determine the clinical involvement 
of other organs. The most frequently described clinical entities were viral myocarditis 
and viral encephalitis. Recognition of these extra- pulmonary complications is critical to 
determining the true burden of influenza infection and initiating organ- specific sup-
portive care.
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1  | INTRODUCTION
Severe acute respiratory viral infections, including influenza, are lead-
ing causes of global morbidity and mortality. Each year, influenza in-
fects approximately 10%- 20% of the world’s population resulting in 
3- 5 million hospitalizations and an estimated 87.1 billion dollars in 
total annual economic burden in the United States alone.1-3 The true 
burden of influenza infection is likely much larger as current estimates 
are based primarily on the recognition of respiratory symptoms (eg, 
influenza- like illness). Epidemiologic investigations and case reports 
indicate that influenza infection often results in diverse phenotypic 
presentations including involvement of organ systems other than 
the respiratory tract. A number of rare, but sometimes severe, syn-
dromes are increasingly being recognized. These extra- pulmonary 
manifestations of influenza are likely the result of either unique viral 
pathogenesis (eg, avian A[H5N1]) or host factors (age, comorbidities, 
genetic predisposition), or both. Most extra- pulmonary complica-
tions are associated with the acute phase of the infection and often 
manifest as the presenting symptoms. Others, particularly the post- 
infectious central nervous system (CNS) syndromes (eg, Guillain- 
Barre syndrome [GBS]) and exacerbations of underlying conditions 
(eg, ischemic heart disease, cerebrovascular disease) may follow in-
fection by weeks to months. In addition, there remains controversy 
regarding the possibility of late onset sequelae (eg, Parkinson’s 
disease). Multiple influenza- associated extra- pulmonary complica-
tions can also occur simultaneously in a single patient.4 Improved 
recognition of these complications will improve the understanding 
of the morbidity and mortality caused by influenza viruses world-
wide and allow for better organ- specific supportive care to reduce 
influenza- associated morbidity and mortality. In an attempt to better 
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understand the burden of extra- pulmonary complications of influenza 
infection, a comprehensive literature review was performed.
1.1 | Search strategy and selection criteria
The authors undertook a comprehensive literature review by query-
ing MEDLINE (PubMed database) for articles in English pertaining to 
extra- pulmonary complications of influenza infection published be-
tween January 1, 1959, and July 1, 2016, using organ- specific search 
terms determined by author consensus (Table 1).
Two authors independently reviewed the abstracts for inclusion. 
Studies that were not in English, included only pediatric populations, 
focused on extra- pulmonary complications of influenza vaccines or an-
tiviral therapy were not included (Figure 1). A separate comprehensive 
review of extra- pulmonary manifestations in pediatric populations is 
concurrently being prepared.
The search terms yielded 2752 articles and 2514 were excluded 
(Figure 1). Two authors independently reviewed 241 articles. For case 
reports and case summaries, specific data regarding demographics, 
clinical features, and outcomes were extracted. References of the 
included articles were also reviewed to ensure complete capture of 
relevant articles.
2  | FINDINGS
2.1 | Cardiovascular complications of influenza
Cardiovascular disease and influenza have long been associated 
due to an overlap in the peak incidence of each disease during win-
ter months. Epidemiologic studies have also noted an increase in 
cardiovascular deaths during influenza epidemics indicating that 
cardiovascular complications of influenza infection, including exacer-
bation of heart failure, acute ischemic heart disease, and less often 
acute myocarditis, are important contributors to morbidity and mor-
tality during influenza infection.5-7 Additionally, studies from vaccine 
and antiviral therapeutic trials also highlight an important associa-
tion and suggest that specific pharmacologic strategies may prevent 
or reduce the risk of many of the cardiovascular complications of 
influenza.8-10
2.1.1 | Myocarditis
Clinically diagnosed myocarditis, based on a combination of symp-
toms, elevated cardiac enzymes, and echocardiographic findings, 
has been reported in approximately 0.4%- 13% of hospitalized 
adult patients with documented influenza.11,12 Myocarditis may, 
however, be a more common feature in fatal influenza infections 
as classic histopathologic findings, including cellular infiltration 
and myocyte necrosis, have been found in 30%- 50% of patients 
at autopsy despite cardiac involvement not being clinically sus-
pected.13-15 Additionally, influenza- related myocarditis often oc-
curs in the absence of more severe respiratory complications as 
only 40% (6/15) of patients with myocarditis in one study also had 
documented pneumonia.16
There have been approximately 44 cases of influenza- associated 
myocarditis in adult patients described in case reports and case series 
(Table 2).15,17-42 Among those reported, 52% (23/44) occurred in men 
and 68% (30/44) occurred in patients under 40 years of age. Although 
much of the information on influenza- associated myocarditis comes 
from Japan, case reports have been published from all regions in-
cluding Europe, the Middle East, North America, the Caribbean, and 
elsewhere in Asia. The association of different influenza strains and 
Organ system MeSH search terms used
Cardiac Arrhythmia, cardiac ischemia, cardiac tamponade, cardiomegaly, 
cardiomyopathy, coronary artery disease, endocarditis, myocardi-
tis, myocardial infarction, heart arrest, heart failure, heart valve 
disease, pericardial effusion, pericarditis, pulmonary heart disease
Neurologic Cerebrovascular accident, encephalopathy, encephalitis, encepha-
lomyelitis, Guillain Barre syndrome, meningitis, Reye syndrome, 
seizure, stroke, transverse myelitis
Ocular Conjunctivitis, optic neuritis, retinopathy, uveal effusion
Renal Acute kidney injury, acute tubular necrosis, glomerulonephritis, 
Goodpasture, hemolytic uremic syndrome, myoglobinuria, 
rhabdomyolysis
Musculoskeletal Myopathy, myolysis, myositis
Hepatic Hepatitis, hepatic vein thrombus, liver disease, portal vein 
thrombus, transaminitis
Hematologic Leukopenia, lymphopenia, thrombocytopenia, disseminated 
intravascular coagulation, embolism, thrombosis, clot, hemolytic 
uremic syndrome, thrombotic thrombocytopenic purpura, 
hemophagocytic syndrome
Endocrine Diabetes mellitus, diabetic ketoacidosis, hyperglycemic hyperos-
molar nonketotic coma
TABLE  1 Description of organ- specific 
MeSH search terms used in literature 
search
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subtypes with myocarditis is limited as 31/44 (70%) involved influenza 
A(H1N1)pdm09. The remaining 12 cases involved influenza B infec-
tion (11%; 5/44), A(H3N2) infection (4%; 2/44), and no subtype was 
reported in 6 others (14%; 6/44).
The clinical course of influenza- associated myocarditis is variable, 
with the majority of patients experiencing an acute onset of symptoms 
related to cardiac dysfunction, including chest pain, dyspnea, syncope, 
hypotension, and arrhythmia, between days 4 and 7 following the 
initial symptoms of viral infection.43 Most patients, with admission 
symptoms reported, presented to the hospital with cardiac symptoms 
(97%; 34/36), suggesting that it was the cardiovascular manifestations 
that were responsible for the patient seeking medical attention rather 
than typical respiratory symptoms. Of the 37 cases that documented 
time to onset of cardiac symptoms, only 3 (8%) developed symptoms 
late in their course as defined by greater than 10 days after initial viral 
symptoms.15,20,36
The severity of influenza- associated myocarditis spans a wide 
spectrum ranging from asymptomatic to severe disease. Although rec-
ognition of influenza- associated cardiovascular complications occurs 
primarily in patients with cardiac symptoms, there is some sugges-
tion that a significant proportion of patients with influenza infection 
may suffer clinically unrecognized, asymptomatic myocardial injury. A 
Japanese study of 96 patients found that 11% of patients who were 
infected with influenza A (H3N2) had elevated myosin light- chain I 
concentrations, a marker for myocardial injury.44 However, the degree 
of injury is likely mild as another study of 152 slightly younger patients 
in the UK found no elevation of cardiac troponin I and T levels, which 
are more sensitive markers of cardiac injury.45 A third study followed 
30 previously healthy young adults diagnosed with influenza infection 
for 28 days after enrollment with serial electrocardiograms, echocar-
diograms, and cardiac enzymes and found that no enrolled patients 
had clinically significant changes in their cardiac studies or cardiac 
enzymes.46
At the other end of the spectrum, a number of cardiac- specific 
complications have been described in the setting of influenza- 
associated myocarditis including heart failure, arrhythmias, peri-
cardial effusion, and cardiac tamponade. Congestive heart failure, 
as diagnosed by regional or global hypokinesis on echo/MRI, is the 
most common complication and is seen in 84% (37/44) of patients 
with influenza- associated myocarditis. More than half (23/37; 62%) 
of patients with heart failure from influenza- associated myocarditis 
required advanced cardiac support therapies. Thirty- eight percent 
(14/37) were treated with intra- aortic balloon pumps (IABP), 27% 
(10/37) with percutaneous cardiopulmonary support, and 16% (6/37) 
F IGURE  1 Results of search strategy
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TABLE  2 Summary of myocarditis cases in the setting of influenza infection reported in the literature (case reports and case series)
Age Sex Virus
Cardiac 
symptoms 
present at 
admission
Onset of 
symptomsa Echocardiographic findings
Elevated 
cardiac 
enzymes
Advanced 
cardiac support Survivalb
17 F A(H1N1) Yes Not reported EF 20%, large effusion Not reported ECMO, BiVAD Y
17 F A Yes 3 d Day 0 with tamponade, normal 
EF 
Day 3 EF 30%
Yes None Y
21 M A(H1N1) Yes 7 d EF 50%, small effusion Yes No Y
24 F A(H1N1) Yes Not reported EF 10%- 15%, moderate 
effusion
No None Y
24 M B No Few weeks Effusion with tamponade Not reported None Y
24 F A(H1N1) Yes 6 d EF 34%, diffuse hypokinesis, 
effusion
Yes PCPS, IABP Y
25 M A(H3N2) Yes 10 d Day 0—normal 
Day 3—pericardial effusion
Yes None Y
25 F A(H1N1) Yes 2 d Reported as myopericarditis Not reported None Y
30 F A(H1N1) No 6 d EF 15%, LV enlargement, 
moderate effusion with 
right- side collapse
Yes None Y
30 F A Yes 5 d EF 20%, global hypokinesis Yes BiVAD Y
30 M A(H1N1) Yes 10 d EF 10% Yes IABP Y
31 M A(H1N1) No 9 d Diffuse hypokinesis, effusion Yes IABP Y
31 F A(H1N1) Yes 2 d Severe hypokinesis Yes PCPS, IABP Y
34 F A(H1N1) No 1 d EF 23%, diffuse hypokinesis Yes PCPS, IABP N
34 F A(H1N1) Yes 7 d EF 45% with regional 
hypokinesia
Yes No Y
34 F B Yes 10 d EF 8%, dilated ventricles, 
hypokinesis, LV thrombus
Yes IABP, LVAD N
35 F A(H1N1) Yes 0 d EF 15% Yes ECMO Y
36 M A(H1N1) Yes 7 d EF 20%, global hypokinesis, 
moderate effusion
Yes PCPS N
36 M A Not reported Not reported Normal No No Y
41 F B Yes 4 d EF 30%, moderate effusion Yes IABP, PCPS N
40 F A(H1N1) Yes 10 d Not reported Not reported Transplant, 
artificial heart
N
43 M B Yes 4 d No Yes No Y
44 M A(H1N1) Yes 5 d Not performed; EF 27% by 
catheterization
Yes ECMO Y
44 M A(H1N1) No 21 d EF 16% Not reported None Y
44 F A(H1N1) No 3 d EF 24% Yes PCPS, IABP Y
47 F A(H1N1) Yes 4 wk EF 15% Not reported ECMO, 
septostomy
Y
48 F A(H1N1) Yes 2 d EF 20% Yes None Y
50 M A(H1N1) Yes 2 d EF 30%, regional hypokinesia No No Y
50 M A(H1N1) Yes 3 d EF 40%, regional hypokinesia, 
four- chamber dilation
Yes None Y
51 F A No 6 d Pericardial effusion with 
tamponade
Not reported None Y
52 F B Yes 6 d EF 10% Yes EBMO Y
52 M A(H1N1) Yes Not reported EF 24% Yes IABP, PCPS N
(Continues)
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who required extracorporeal membrane oxygenation. Two patients 
had a biventricular assist device (BiVAD) implanted, one had a left 
ventricular assist device placed, one had a surgical atrial septostomy 
performed, and one patient underwent a heart transplant which failed 
requiring placement of an artificial heart (Jarvik).
Although heart failure associated with influenza can be severe 
and cause significant hemodynamic compromise requiring advanced 
cardiac support therapies, recovery of cardiac function has been 
documented frequently in survivors. Of the 37 patients who were 
diagnosed with heart failure in the setting of influenza- associated 
myocarditis, with ejection fractions ranging from 8% to 50%, 26 (70%) 
ultimately experienced resolution of their systolic dysfunction on 
echocardiogram. All of the patients (n = 13) who had time to resolution 
reported did so within 20 days of the onset of dysfunction.
Pericardial effusions of variable size and significance also fre-
quently complicate influenza- associated myocarditis. Thirteen of 44 
(30%) patients with influenza- associated myocarditis had pericardial 
effusions on echocardiogram, and 4 had evidence of tamponade re-
quiring pericardiocentesis. Other reported complications include eight 
cases of life- threatening ventricular arrhythmias and one case of myo-
cardial infarction (MI). Additionally, recurrent myocarditis in the set-
ting of influenza infection has been reported in 2 cases. One patient 
had two prior episodes of myocarditis and then a third elicited in the 
setting of influenza infection, consistent with influenza infection exac-
erbating an underlying condition.29 Another patient had resolution of 
his influenza- associated myocarditis followed by recurrent myocarditis 
22 days after initial presentation.29,33
The underlying pathophysiology of influenza- associated myo-
carditis remains unclear. In a study of endomyocardial biopsies from 
38 patients with viral and non- viral mediated myocarditis, the viral 
etiology was determined by PCR in 20 patients including 2 with in-
fluenza.47 In another study of 29 patients with fatal influenza B in-
fection with cardiac tissue samples available at autopsy, only one 
patient had influenza B detected by RT- PCR.13 Of the case reports 
described above, the pericardial fluid of one patient was found to be 
positive for influenza A(H1N1)pdm09by PCR,.24 Another patient had 
evidence of influenza A(H1N1) in her myocardium identified by both 
immunofluorescence and viral culture after her heart was replaced by 
a Jarvik artificial heart on hospital day 4; in this case, influenza A was 
also detected in her blood.32 Evidence of virus in these cases suggests 
a potential role for direct viral invasion as the underlying pathogenic 
mechanism, although PCR positivity alone does not provide definitive 
evidence. Alternatively, the increased incidence of myocarditis among 
patients with more severe influenza infection may implicate an exag-
gerated immune response in the pathogenesis, as increased serum 
cytokines are commonly found in severe influenza.48-52 Increasing 
levels of IL- 8, IL- 10, IL- 6, and TNF- α were reported in one patient 
with influenza- associated myocarditis concurrent with her clinical de-
terioration supporting the role of systemic inflammation as a driver 
of influenza- associated myopericarditis.53 Similarly, elevated levels of 
TNF- α mRNA and protein were found in endomyocardial biopsies from 
16 of 20 (80%) patients with viral myocarditis compared with 3 of 19 
(17%) patients with non- viral etiologies of myocarditis.47 Early recog-
nition is critical as many patients required advanced cardiac supportive 
Age Sex Virus
Cardiac 
symptoms 
present at 
admission
Onset of 
symptomsa Echocardiographic findings
Elevated 
cardiac 
enzymes
Advanced 
cardiac support Survivalb
52 M A(H3N2) Yes 7 d EF 28% Yes IABP Y
53 M A(H1N1) No 3 d EF 40%, diffuse hypokinesis Yes None Y
58 M A(H1N1) Yes 10 d EF 30%- 34%, diffuse 
hypokinesis
Yes None Y
60 F A(H1N1) Yes 3 d EF 10% with global hypokine-
sis and dilated left atrium
Not reported IABP, PCPS, 
ECMO
Y
61 M A(H1N1) Yes 2 d EF 20% Yes IABP Y
61 F A(H1N1) Yes 2 d EF 20%, diffuse hypokinesis Yes None Y
64 M A Yes Not reported EF 24%, left ventricular 
hypertrophy
Yes IABP, PCPS N
66 M A(H1N1) No 7 d Normal Yes None Y
67 M A(H1N1) Yes 3 d EF 20%, global hypokinesis Yes IABP N
69 M A(H1N1) No 8 d EF 29%, diffuse hypokinesis Yes PCPS N
72 M A(H1N1) Yes 2 d EF 38%, diffuse hypokinesis Yes None Y
75 M A Yes Not reported Global hypokinesis Yes None N
EF, ejection fraction; ECMO, extracorporeal membrane oxygenation; BiVAD, biventricular assist device; PCPS, percutaneous cardiopulmonary support; 
IABP, intra- aortic balloon pump; LVAD, left ventricular assist device.
aOnset of cardiac symptoms from initial viral symptoms.
bSurvival until hospital discharge.
TABLE  2  (Continued)
     |  377SELLERS Et aL
care, and the mortality among the reported 43 patients with influenza- 
associated myocarditis is approximately 23%.
Heart failure independent of myocarditis has also been described 
in the course of influenza infection. In one series of 124 patients 
hospitalized with influenza infection, 24 had echocardiograms (echo) 
performed and 6 (25%) of those patients had new or worsened left 
ventricular dysfunction.54 Four of these patients experienced at least 
partial improvement in ejection fraction by echo at 4- 22 days. A sec-
ond retrospective, multicenter study looked at 23 ICU patients with 
A(H1N1)pdm09 infection and found that right ventricular dysfunc-
tion (48%) was more common than left ventricular dysfunction (17%) 
and was higher in prevalence than generally reported in patients with 
acute respiratory distress syndrome (ARDS) (10- 25%).55
2.1.2 | Ischemic heart disease
Several large epidemiologic studies in Russia, the United States, the 
United Kingdom, and Hong Kong have revealed a temporal associa-
tion between the circulation of influenza viruses and an increase in 
hospitalizations and deaths due to ischemic heart disease (IHD).5,56-58 
Additionally, a significant increase in the number of IHD deaths has 
also been detected during epidemic periods.57 Two large studies uti-
lizing self- controlled case series analysis found that rates of a first MI 
were highest in the first 3 days following an acute respiratory infec-
tion with a reduction in the effect over time.6,58 Another study of 600 
patients in the Veterans Administration system found that 143 (24%) 
patients who tested positive for influenza had acute cardiac injury, 
80% of which occurred within 3 days of the influenza diagnosis and 
70 (49%) were MIs. The remaining half had elevations in cardiac bio-
markers due to acute congestive heart failure (8/143; 6%), myocardi-
tis (6/143; 4%), atrial fibrillation (4/143; 3%), non- cardiac explanations 
(11/143; 8%), or no documented explanation (44/143; 31%).59 In con-
trast, only 13 (3.6%) of 2287 patients diagnosed with an unspecified 
community- acquired pneumonia (CAP) were diagnosed with MI in the 
30 days after CAP diagnosis.60
Given the association between peak influenza activity and cardio-
vascular events, studies have evaluated the effect of influenza vacci-
nation on the reduction of multiple cardiovascular end points (Table 3). 
The incidence of acute MI was significantly reduced in the 60 days 
following influenza vaccination in one self- controlled case series of 
the inactivated influenza vaccine.61 This effect was most pronounced 
in the first 2 weeks after vaccination with a reduction of acute MI by 
32% (incidence rate ratio, IRR, 0.68; 95% CI 0.60- 0.78) and decreased 
to 18% (IRR 0.82; 95% CI 0.75- 0.90) at 25- 59 days post- vaccination. 
Similarly, a larger prospective randomized double- blinded placebo 
controlled study of 658 patients with coronary artery disease (CAD) 
found a significant reduction in coronary ischemic events, specifically 
cardiovascular death, MI, cardiac revascularization, or hospitalization 
with myocardial ischemia, in the 12 months following influenza vac-
cination with the inactivated influenza vaccine compared to subjects 
receiving a placebo vaccine (HR 0.54; 95% CI 0.29- 0.99).62 A case- 
control trial in the UK evaluated over 75 000 patients for an associa-
tion between influenza vaccination and the diagnosis of a first acute 
MI between 2001 and 2007 and found that vaccination within the 
previous year was associated with a lower rate of acute MI (OR 0.81; 
95% CI 0.77- 0.85).63
A number of studies evaluating the impact of influenza vaccina-
tion on subsequent cardiovascular events have yielded mixed results. 
In the FLUVACS study, the 100 subjects with a new MI who were 
randomized to receive an inactivated influenza vaccine experienced 
a significant decrease in the composite end point of cardiovascular 
death, non- fatal MI, or severe ischemia at 6 months (RR 0.50; 95% 
CI 0.29- 0.85) compared with those who received placebo.8 Similarly, 
a case- control study of 218 patients with CAD in the United States 
demonstrated that the influenza vaccine was protective against a new 
MI in subjects who had already experienced an MI (OR 0.33; 95% CI 
0.13- 0.82).9 However, a separate retrospective study of 1378 patients 
who had survived a prior MI found no association between influenza 
vaccination and reduction in a subsequent MI.64 Taken together, these 
studies strongly suggest that influenza vaccination is associated with 
a reduction in initial MIs, while larger studies on secondary prevention 
are needed.
Only one retrospective study has evaluated the effect of neur-
aminidase inhibitors on the recurrence rate of cardiovascular dis-
ease following influenza infection.10 Patients with a prior history of 
cardiovascular disease and acute influenza infection were prescribed 
oseltamivir and those who filled with prescription within 2 days suf-
fered fewer recurrent MIs (0.2% vs 1.4%; P < .005) and less combined 
cardiac events, including MI, angina, stroke, heart failure, and sudden 
cardiac death compared with untreated patients within 30 days of in-
fluenza diagnosis (OR 0.417; 95% CI 0.35- 0.50). The low percentage 
of people who filled their prescription within 2 days (18.2%) represents 
a potentially important missed opportunity to reduce cardiovascular 
complications from influenza infection.
Influenza- associated IHD is posited to be driven by inflammation 
which is known to have a critical role in the development of acute 
coronary syndrome.65 In apolipoprotein E- deficient mice, an animal 
model of atherosclerosis, animals that were infected with influenza 
A virus developed subendothelial and smooth muscle inflammatory 
infiltration with overlying platelets and fibrin strands in atheroscle-
rotic plaques.66 Additionally, the systemic pro- inflammatory response 
triggered by influenza infection is accompanied by significant pro- 
coagulant effects which may also play a role.67
Viremia in influenza infection has been reported variably—one 
study of 139 patients with influenza A(H1N1)pdm09 infection re-
ported viral RNA detected by RT- PCR in 14 patients (10%), which was 
associated with severe clinical disease and presence of the D222G/N 
mutation in the viral hemagglutinin protein.68 Earlier studies in non- 
pandemic influenza strains identified viremia in up to 17% of pa-
tients.69 At present, no human studies support the theory of direct 
virus invasion of the vascular bed. However, influenza A virus has been 
detected in the atherosclerotic arteries of apolipoprotein E- deficient 
mice that were infected, suggesting that this is a possibility.70 There 
is also limited evidence, however, that prior infection may play a role 
in the development of chronic atherosclerosis. One cross- sectional 
study of patients referred for cardiac catheterization found that while 
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influenza IgG seropositivity is not independently associated with IHD 
alone, patients who were seropositive for multiple pathogens were 
more likely to have IHD suggesting that cumulative infection burden 
may be related to development of atherosclerosis.71
2.1.3 | Stroke
Similar to ischemic cardiac complications, the risk of ischemic cer-
ebral vascular accidents (CVA), or strokes, appears to be significantly 
increased in the days after a respiratory tract infection.58 However, 
only two cases of ischemic CVA in the setting of influenza infection 
have been reported. One case of multiple strokes occurred in a young 
woman with disseminated intravascular coagulation who was critically 
ill.72 The other case occurred in a 50- year- old woman with ARDS sec-
ondary to influenza A(H1N1) who developed multiple strokes in the 
territory of the right middle cerebral artery.73 There may be indirect 
evidence of an association between influenza and CVAs, but data 
from influenza vaccination and neuraminidase inhibitors are conflict-
ing.74,75 One case- control study in France found that the risk of stroke 
was reduced in subjects vaccinated in that year compared to those not 
vaccinated (OR 0.50, 95% CI 0.26- 0.94). Protection was strongest in 
patients under the age of 75.76 Similarly, another study in Germany 
also found a reduced risk for stroke with influenza vaccination (OR 
0.46, 95% CI 0.28- 0.77).77 When stratified by type of stroke, the re-
duced risk was most significant for ischemic stroke with a trend toward 
protection in hemorrhagic stroke and no protection against transient 
ischemic attacks (TIA). In contrast, a large study of over 23 000 pa-
tients from two prospective cohorts (OPTIC and ARMISTAD) and a 
randomized trial (PERFORM) did not find any association between in-
fluenza vaccination and cerebrovascular accidents, although patients 
in this study had higher levels of known CVA risk factors including dys-
lipidemia and hypertension.78 In this study, propensity score match-
ing was used to compensate for potential healthy user bias that may 
explain the significant benefit seen in previous studies. Lastly, there is 
evidence that treatment with the neuraminidase inhibitor oseltamivir 
in the setting of acute influenza infection reduces the risk of stroke.79 
The protective effect remained significant in patients under the age 
of 65 for 6 months after infection, whereas in patients 65 and older, 
the association was significant only in the first month after infection.79
Cardiac complications associated with influenza infection, includ-
ing myocarditis, ischemic heart disease, and stroke, can have a signifi-
cant impact on influenza mortality and morbidity. Early recognition of 
these complications is critical to initiate organ- specific supportive care 
Additionally, the protective role of influenza vaccines against an initial 
MI and early initiation of neuraminidase inhibitor with a decrease in 
combined cardiovascular end points highlights important preventative 
and therapeutic opportunities to reduce influenza- associated cardio-
vascular complications.
2.2 | Neurologic complications of influenza
Influenza infection can lead to a variety of neurologic complications 
including a number of specific clinical entities grouped together as 
influenza- associated encephalitis or encephalopathy (IAE), as well 
as a separate syndrome known as post- influenza encephalitis, GBS, 
Reye’s syndrome, and Parkinsonian symptoms. While neurologic 
complications are more frequently noted in pediatric populations, 
they are also increasingly being recognized in adults.80 The neurologic 
manifestations of influenza have been primarily reported in Japan, 
which may be due to greater recognition in that region. However, a 
study of influenza- associated neurologic complications in the USA 
did find that a disproportionate number of Asian/Pacific Islanders 
were affected (12.79/1 000 000) compared with white, non- Hispanic 
patients (3.09/1 000 000) suggesting a possible underlying genetic 
predisposition.81
2.2.1 | Influenza- associated encephalitis/
encephalopathy
Influenza- associated encephalopathy or encephalitis (IAE) is a rapidly 
progressive encephalopathy primarily characterized by an impaired 
level of consciousness developing within a few days of influenza in-
fection. A number of distinct clinical syndromes have been described, 
predominantly in the pediatric literature, and fall under the umbrella 
category of IAE including acute necrotizing encephalopathy (ANE), 
acute encephalopathy with biphasic seizures and late reduced diffu-
sion (AESD), and mild encephalitis/encephalopathy with reversible 
splenial lesion (MERS). ANE is often a fulminant complication char-
acterized by multiple brain lesions frequently involving the thalami. 
AESD is characterized by a biphasic course, febrile seizures, and sub-
cortical white matter lesions on MRI, whereas MERS, which is charac-
terized typically by a lesion of the splenium of the corpus callosum, is 
associated with a milder course and often a good clinical outcome.82 
The spectrum of influenza- associated encephalitis can also be ex-
panded to include posterior reversible encephalopathy syndrome 
(PRES), which is associated with areas of edema on MRI and can occur 
days to weeks after initial viral symptoms, and acute hemorrhagic 
leukoencephalopathy (AHLE), characterized by a rapid and fulminant 
demyelination and inflammation of the white matter. However, these 
entities are primarily described in the pediatric literature as IAE is 
more frequently recognized and reported in children less than 5 years 
of age. The incidence of IAE in adults has been reported in up to 4% of 
hospitalized adults, although case reports rarely apply the terminology 
of specific clinical syndromes beyond IAE.83
There have been 28 reported cases of IAE in adults with 7 fur-
ther differentiating the clinical syndromes including 3 cases of PRES, 2 
cases of MERS, and 2 cases of AHLE (Table 4).4,84-104 In these reports, 
men are more often affected (19/28; 68%) and patients range in age 
between 20 and 86 years old. The neurologic symptoms appear early 
in the disease course, within the first week of viral illness in 22 of 25 
(88%) cases that reported the time of onset. Most patients (20/25; 
80%) presented to the hospital with neurologic symptoms. Almost 
all patients (25/27, 93%) experienced symptoms of decreased con-
sciousness, and 37% (10/27) had witnessed seizure activity. Other 
less common presenting symptoms included urinary retention, vision 
loss, hemiplegia, cerebellar signs, and opisthotonus. Of the 28 cases of 
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adult IAE reported, 17 (61%) were in the setting of influenza A(H1N1) 
infection, 4 (14%) were attributable to influenza A(H3N2) infection, 3 
(11%) occurred during influenza B infection, and 4 (14%) were second-
ary to unspecified influenza A viruses.
In 18 cases with CT scans reported, 7 (39%) had acute abnor-
malities including 3 (17%) with patchy hypodense lesions on the 
vertex and the in the thalamus, 2 (11%) with diffuse edema, 1 (5%) 
with focal left parietal and occipital cortical edema, and 1 (5%) with 
superior sagittal thrombosis and cerebral hematomas. Nine (50%) 
adult patients with IAE had normal CT scans, and the remaining two 
patients (11%) had evidence of chronic changes. Of the 10 patients 
with MRI results reported, all were abnormal, primarily involving sig-
nal abnormalities throughout the cortex, white matter, or brainstem. 
Three patients (30%) were diagnosed with PRES based on findings of 
vasogenic edema in the frontal cortex in one and in the parietal and 
occipital cortex in the other two; only one of these patients had fol-
low- up MRI imaging which demonstrated resolution at day 24.4,91,101 
Two patients’ MRIs had the hyperintense signal on the central sple-
nium of the corpus callosum typical of MERS; follow- up MRI at day 11 
was normal in the only patient with follow- up imaging reported.98,104 
Electroencephalography (EEG) testing revealed diffuse slowing typical 
of encephalitis in 11/14 (79%), epileptic discharges in 1/14 (7%), and 
was normal in 1/14 (7%).
Lumbar puncture (LP) was performed in 24 of 28 patients and 
demonstrated a pleocytosis in 4 cases (17%), elevated protein in 4 
cases (17%), and was normal in 11 cases (46%). RT- PCR was positive 
for influenza in 5 of the 24 (21%) patients that had a lumbar puncture 
(LP) performed.92,94,95 None of these patients received systemic corti-
costeroids prior to the LP. Similarly, the post- mortem examination of 
two patients that died of IAE yielded viral RNA isolated from the brain; 
however, there was no discussion of whether the location of the viral 
RNA correlated to imaging findings.89,90
All patients were treated with supportive care, and 21 of the 28 
patients reported were treated with neuraminidase inhibitors includ-
ing oseltamivir, peramivir, and/or zanamivir. Three patients (11%) were 
additionally treated with corticosteroids, and one patient underwent 
plasma exchange.85,87,98 Overall, 79% (22/28) of adult patients with 
IAE survived. However, 25% (7/28) of patients suffered residual neu-
rologic defects, primarily including motor weakness and cognitive 
defects at follow- up within 3 months of the initial illness. Long- term 
follow- up beyond 3 months has not been reported.
A separate entity, post- influenza encephalopathy has also been 
described, in which the development of neurologic symptoms occurs 
after the resolution of the respiratory symptoms but within 3 weeks 
of the influenza diagnosis.83 One case report described post- influenza 
encephalopathy, including altered mental status, seizures, involun-
tary movements, and cortical blindness that developed 3- 4 weeks 
following a severe respiratory disease with influenza A(H1N1) virus 
infection.105 The patient’s MRI demonstrated diffuse multifocal le-
sions with both gray and white matter. In a study of 20 patients with 
encephalopathy in the setting of influenza, fourteen patients were 
classified as having post- influenza encephalopathy, with development 
of neurologic symptoms at a median of 9.5 days (range, 7- 23 days).83 A
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Of the twelve patients who had MRIs performed, six (50%) had MRI 
abnormalities which demonstrated demyelination, suggesting a differ-
ent pathophysiology of late- developing neurologic symptoms in which 
immunologic mechanisms are likely operative.
The pathogenesis of influenza- associated encephalopathy and en-
cephalitis in adults remains undefined. Demonstration of viral RNA, 
as detected by rRT- PCR, in brain tissue and CSF suggests direct viral 
invasion of the CNS.106-109 Patients with IAE more frequently experi-
ence concurrent hepatic and renal function dysfunction, which could 
suggest a component of metabolic encephalopathy coexisting with 
severe influenza illness rather than as a direct effect of the virus it-
self.83 A dysregulated immune response has also been posited to drive 
neurologic complications in influenza. Serum levels of cytokines IL- 6, 
TNF- alpha, and IL- 10 were found to be significantly elevated in pe-
diatric patients with IAE as compared to influenza- infected patients 
without neurologic involvement.110,111 Similarly, CSF levels of IL- 6 
were also found to be significantly elevated in pediatric patients with 
IAE compared to children with neurologic disorders and not infected 
with influenza.112 Transcriptomic profiling has also demonstrated ele-
vated levels of IL- 6, IL- 10, and TNF- alpha mRNA in patients with IAE 
compared to those with influenza- associated febrile seizures in the 
setting of equivalent viral loads.111 One study demonstrated signifi-
cantly greater serum levels of soluble CD163, a scavenger receptor 
for hemoglobin- haptoglobin complexes expressed by monocytes and 
macrophages in patients with more severe forms of IAE such as ANE 
compared to those with milder disease suggesting a dose- response 
association.113
Although IAE has been described in case reports from around the 
world, there appears to be a higher incidence in East Asian popula-
tions, suggesting the possibility of a genetic predisposition. In a study 
of 29 Japanese patients with AESD or ANE, a higher frequency of sev-
eral single nucleotide polymorphisms in the carnitine palmitoyl trans-
ferase II gene was found compared with healthy controls.114 Another 
study identified an association between AESD and a genetic variant of 
the adenosine A2A receptor (ADORA2A) which may alter cyclic AMP 
signaling.115 Finally, missense mutations in the gene encoding Ran 
binding protein 2 (RANBP2) have been identified in a Taiwanese fam-
ily in which 16 family members were diagnosed ANE.116 RANBP2 is a 
ubiquitin ligase that mediates nuclear transport of HIV pre- integration 
complexes and represses replication of Japanese encephalitis virus in 
vitro [REFS]; these studies imply that altered viral processing may allow 
a highly adapted respiratory virus to become active in the CNS.116,117-
119 However, much of the data supporting a role for host genetics or a 
dsyregulated immune response in IAE comes from studies in pediatric 
populations. Further studies in adults are needed to determine the role 
of host response in the pathogenesis of IAE.
2.2.2 | Guillain- Barre syndrome
Guillain- Barre syndrome is an acute immune- mediated polyneuropa-
thy characterized by progressive ascending symmetric muscle weak-
ness and accompanied by absent deep tendon reflexes. Most cases 
of GBS are thought to represent an autoimmune response triggered 
by an infectious agent with onset of symptoms within 2- 6 weeks 
of the initial infection, most commonly with Campylobacter jejuni, 
Mycoplasma pneumoniae, or Epstein- Barr virus. However, 60%- 70% 
of cases of GBS in Western countries do not have a clear etiology 
identified, although influenza has been proposed as an additional 
causative agent.120
Guillain- Barre syndrome secondary to influenza infection was 
first described in 1959, and five adult cases have been reported 
since.121-124 Two of the 5 patients (40%) were women, and 4 of 5 
(80%) were under the age of 40. All cases of influenza- associated 
GBS occurred in the setting of influenza A virus infection, and 40% 
(2/5) were from pandemic H1N1. In contrast to other infectious 
agents, the majority of patients with influenza- associated GBS devel-
oped neurologic symptoms within 1 week of the onset of influenza- 
like illness. The fifth patient experienced a delayed onset of GBS 
symptoms approximately 5 weeks after influenza infection.121 Of 
the 5 cases of influenza- associated GBS, two patients received treat-
ment with IVIG and survived with resolution of their symptoms by 
1 month; one patient was treated with plasma exchange and sur-
vived although it was not reported whether symptoms resolved or 
not. Two patients did not receive any disease- modifying treatment 
and both died.124
Epidemiologic studies that have evaluated an association between 
preceding influenza and GBS suggest that influenza may be an import-
ant and under- recognized etiology of GBS.125-127 In a nested case- 
control study in the UK, researchers found that influenza- like illness 
carried an 18- fold increase risk for GBS in the 2 months following in-
fectious symptoms (OR 18.6 95% CI 7.5- 46.4).125 Similarly, there is a 
temporal association between influenza infection and GBS with an in-
creased relative incidence of GBS within 30 days (16.64 95% CI 9.37- 
29.54) and 90 days (7.35 95% CI 4.36- 12.38) following presentation 
with an influenza- like illness.128 In a study of 405 French patients with 
GBS, peaks in the incidence of cases without an identified etiologic 
agent are also temporally associated 1- 2 months following peaks in 
the incidence of influenza- like illnesses.120 In an additional analysis of 
73 patients with GBS without a clear etiology in the same study, 10 
(13.7%) had serologic evidence of recent influenza A infection and 4 
(5.5%) with recent influenza B infection.
Although the 1976 influenza swine flu vaccination program was 
stopped prematurely due to the increased development of GBS in 
subjects who received this particular vaccine, recent studies of sea-
sonal influenza demonstrate a safe reduction in GBS in vaccinated 
individuals. Evidence from a study in the UK demonstrated no in-
creased risk of GBS associated with the seasonal influenza vac-
cine.129 Similarly, a Canadian study using universal healthcare system 
databases to examine the risk of GBS after exposure to the seasonal 
trivalent inactivated influenza vaccine found a lower attributable 
risk of admission for GBS (1.03 per million healthcare encounters 
for influenza) for those vaccinated compared with unvaccinated in-
dividuals (17.2 per million healthcare encounters for influenza).130 
Taken together, these studies demonstrate that while there may be 
an increase in GBS associated with influenza infection, vaccination 
appears to be protective.
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While the mechanism underlying influenza- associated GBS is not 
known, evidence from C. jejuni- induced GBS suggests that molecular 
mimicry may play a role as the C. jejuni lipopolysaccharide induces an 
antiganglioside antibody response resulting in the immune- mediated 
polyneuropathy of GBS. However, of the five cases of influenza- 
associated GBS reported, only one patient had detectable antiganglio-
side antibodies.121 Additionally, in a study of 23 patients infected with 
influenza A(H1N1)pdm09, only one patient tested weakly positive for 
one antiganglioside antibody, anti- GM1, and none of the influenza- 
infected patients were diagnosed with GBS.131
Closely related to GBS are the neuro- inflammatory demyelinating 
diseases, acute disseminated encephalomyelitis (ADEM) which affects 
both the brain and spine and transverse myelitis which affects the 
spine. Both conditions can occur as post- infectious complications and 
influenza have been implicated as an etiologic agent. There have been 
six cases of ADEM, and one case of transverse myelitis in adults after 
influenza infection reported in the literature.105,132-136 In these cases, 
all patients presented with focal myasthenia and paresthesia. Some 
patients also had areflexia or hypotonia and 3/7 (43%) had urinary 
retention. In all cases, MRI imaging demonstrated characteristic T2 
hyperintense lesions throughout the brain and/or spinal cord. Post- 
infectious ADEM and transverse myelitis are thought to represent an 
autoimmune process triggered by the infection that is hypothesized to 
share antigentic features with antibodies directed at myelin proteins. 
One patient with influenza- associated transverse myelitis was found 
to have high titers of myelin oligodendrocyte glycoprotein antibodies, 
suggesting a pathogenic role.137 Additionally, one patient had recur-
rent ADEM after a second influenza infection 6 months after his first 
episode and another had recurrent ADEM after an influenza vaccina-
tion suggesting a role for genetic predisposition or formation of an 
immunologic mechanism.132,135
2.2.3 | Other neurologic complications of 
influenza infection
Narcolepsy is a sleep disorder characterized by excessive daytime 
sleepiness with nighttime disturbance and can be associated with cata-
plexy, the sudden loss of muscle tone triggered by strong emotions. It 
is caused by loss of neurons in the hypothalamus that secrete hypocre-
tin, neuropeptides involved in regulation of arousal and wakefulness. 
However, upper respiratory infections have also been loosely linked 
to disease presentation given a temporal association between infec-
tion and narcolepsy symptom onset, including Streptococcus pyogenes 
infection.138 A retrospective analysis of the onset of narcolepsy in 629 
patients in China demonstrated a threefold increase in the incidence of 
narcolepsy after the 2009 H1N1 influenza pandemic.139 In this study, 
96% of patients who developed narcolepsy following the pandemic did 
not report a prior H1N1 vaccination, suggesting that the association 
was with the virus itself as opposed to the vaccine.
Narcolepsy has long been thought of as a T- cell- mediated auto-
immune disease given its association with the HLA- DQB1*06:02 
genotype.138 However, a recent study of a mouse model lacking B 
and T cells demonstrated sleep patterns consistent with narcolepsy 
following infection with influenza A(H1N1) virus.140 By week 4 follow-
ing infection, viral antigens could be detected in the lateral hypothala-
mus along with loss of up to half of the hypocretin-secreting neurons 
in some brains, suggesting direct viral invasion as a potential mecha-
nism. However, the relationship between influenza infection and the 
development of narcolepsy in humans remains unclear.
Reye’s syndrome, a rapidly progressive disease characterized by 
encephalopathy and fatty infiltration of the liver, has been associated 
with viral infections including influenza treated with acetylsalicylic 
acid. Although this was predominantly seen in children, adult cases 
were reported in the 1970s and 1980s.141,142 Since the recognition 
of the role of acetylsalicylic acid in Reyes syndrome, there has been a 
steep decline in the incidence of reported cases due to the avoidance 
of aspirin in the treatment of viral infections.143
Encephalitis lethargica (EL) is a neuropsychiatric disorder charac-
terized by sleep disturbances, lethargy and symptoms of basal gan-
glia dysfunction, or post- encephalitic Parkinsonism, which includes 
movement disturbances, abnormal gait, increased muscle tone, and 
tremor, first described during the 1918 Spanish flu epidemic. Given 
the temporal association with the 1918 epidemic, influenza was 
thought to be the causative agent for EL. Later neuropathologic stud-
ies of brain tissue from patients with EL during the 1918 epidemic 
found no evidence of viral antigen.144,145 There have been no further 
EL epidemics since the 1920s although sporadic cases are reported, 
often following pharyngitis but without documented influenza infec-
tion.146,147 One early study did identify the presence of influenza A 
viral particles by immunofluorescence in the brains of six patients 
who died with non- epidemic post- encephalitic Parkinsonism, but no 
evidence of influenza was found in the brains of 5 patients with id-
iopathic Parkinson.148 Additionally, another study did demonstrate 
the presence of influenza A viral particles by immunofluorescence 
in the substantia nigra pars compacta of post- mortem brains from 
5 cases of Parkinson disease and 7 cases of Lewy body dementia 
but this finding has yet to be replicated.149 The relationship between 
encephalitis lethargica, Parkinson disease, and influenza infection re-
mains unclear. However, a population based case- control study of 
patients with Parkinson disease (PD) and Parkinson symptoms with-
out a firm diagnosis (PS) found that recent influenza infection in the 
last 29 days was associated with development of PS (OR 3.03, 95% 
CI 1.94- 4.74) but not with PD supporting the idea that influenza in-
fection is associated with transient neurologic sequelae as seen in 
many of the complications discussed above.150
The neurologic complications of influenza infection are extremely 
variable in presentation and strength of association. In particular, IAE 
is poorly described in adults and requires MRI for diagnosis in 50% of 
cases despite being associated with death in 21% of reported cases. 
Low threshold for diagnostic evaluation and early initiation of antiviral 
treatment and supportive care remains critical.
2.3 | Musculoskeletal complications of influenza
While myalgias are a common complaint among individuals with 
many viral infections, the development of rhabdomyolysis represents 
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a less common but more serious complication. In cases of virus- 
associated rhabdomyolysis, influenza is identified as the most com-
mon etiology.151,152
There have been approximately 27 reported cases of rhabdomyoly-
sis in the setting of influenza infection, although this likely represents 
a small fraction of the total cases as myositis and/or rhabdomyoly-
sis have infrequently been reported prior to the 2009 A(H1N1) pan-
demic (Table 5).4,22,152-165 Among 18 patients in Mexico with influenza 
A(H1N1)pdm09 infection, 62% of patients had mild- to- moderate ele-
vations of creatinine kinase (CK).166 Of the 27 patients reported with 
influenza- associated rhabdomyolysis, 15 (55%) were women and 12 
(44%) were over the age of 60. The majority of these patients were in-
fected with influenza A as 37% (10/27) were positive for A(H3N2), 14% 
(4/27) were positive for A(H1N1), and 40% (11/27) had an unspecified 
influenza A virus. Only two patients (7%) were infected with influenza B.
The onset of myopathy related symptoms typically begins early 
in the course of infection, with 93% (25/27) of patients reporting 
symptoms within 1 week of the onset of respiratory symptoms. 
Seventy percent (19/27) presented with muscle tenderness, and 
33% (9/27) presented with weakness or inability to stand. As myal-
gias are a common symptom in viral illness, the diagnosis of rhabdo-
myolysis relies on evidence of muscle necrosis. Although elevation 
of creatine kinase (CK) levels was seen in all patients, a higher de-
gree of elevation was associated with worse outcomes. Elevations 
of CK in influenza infection are associated with longer duration of 
mechanical ventilation (15 days vs 11 days, P < .001) and longer 
median ICU length of stay (13 days vs 8 days, P = .01).167 Seven 
patients had muscle biopsies obtained in their evaluation—one was 
normal and the other six demonstrated varying degrees of necro-
sis, regeneration, and edema—all of which can be consistent with a 
TABLE  5 Summary of cases of myositis in the setting of influenza infection reported in the literature (case reports and case series)
Age Gender Virus
Onset of 
symptomsa CPKb Renal failure? RRT Survivalc
19 M A(H1N1) Not reported 1715 U/L (43- 156) Yes No N
20 M A 3 d 8413.35 mkat/L Yes Yes Y
21 F A 3 d 213 000 IU/L Yes Yes Y
25 M A(H3N2) 10 d 5555 U/L Yes No Y
28 F A 1 wk >3000 μ/L (10- 120) Yes Yes Y
28 F A(H1N1) Few days 1371 U/L (43- 156) Yes No Y
28 F A(H1N1) 1 wk 27 820 U/L (13- 156) No No Y
31 F A 4 d >100 000 IU/L (<200) Not reported Not 
reported
Y
37 M A 1 wk 3100 ukat/L Yes Yes Y
44 M B 4 d 74 550 U/L Yes Yes Y
47 M B 7 d 157 IU/mL No No Y
47 M B Not reported 218 IU Possible No Y
53 F A 1 wk 20 000 μ/L (10- 120) Yes Yes N
57 F A 5 d 203 U/L Yes Yes Y
59 M A(H1N1) 1 wk >41 000 U/L Yes Yes Y
60 F A(H3N2) 6 d 4221 IU/L Not reported No Y
65 M A 1 wk 17 739 IU/L (<170) Yes Yes Y
69 M A 1 d 810 μkat/L Yes Yes Y
70 F A(H3N2) 2 d 4432 IU/L (<40- 180) No No Y
74 M A(H3N2) 3 d 1365 U/L Yes Yes N
75 F A(H3N2) 2 d 1198 IU/L (<40- 180) No No Y
76 F A(H3N2) 1 d 1138 IU/L (<40- 180 No No Y
76 F A 1 wk 35 000 U/L (10- 120) Yes Yes Y
77 M A(H3N2) 7 d 3827 IU/L Not reported No Y
78 F A(H3N2) 3 d 25 832 IU/L (<40- 180 No No Y
82 F A(H3N2) 2 d 2405 IU/L (<40- 180) No No Y
86 F A(H3N2) 2 d 9829 IU/L (<40- 180 No No Y
RRT, renal replacement therapy.
aOnset of muscular symptoms from initial viral symptoms.
bValues are not standardized units, institutional normal range reported in parenthesis when available.
cSurvival to hospital discharge.
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diagnosis of rhabdomyolysis. Of four patients with myoglobin tested 
in urine, all were positive.
Rhabdomyolysis can lead to renal failure by tubular obstruction 
from excess myoglobin, direct tubular injury, or vasoconstriction of 
renal blood vessels. Of the 27 reported cases, 16 patients (59%) had 
renal failure and 12 (44%) ultimately required renal replacement ther-
apy (RRT). Outcomes for the twelve patients who required RRT were 
generally good with 10 (83%) recovering kidney function without the 
need for RRT beyond hospitalization, 1 died, and another required RRT 
beyond discharge.
While in vitro studies have demonstrated the ability of influenza to 
infect human skeletal muscle, this has not been reliably demonstrated 
in vivo as there have been only two cases in which influenza virus has 
been isolated from the muscle tissue of patients with rhabdomyoly-
sis.164,168-170 Histopathologic evaluation of affected muscle argues 
against an inflammatory myopathy as biopsies reveal patchy necro-
sis with little inflammatory infiltration.171,172 Early recognition of this 
influenza- associated complication is necessary to institute aggressive 
therapy for myositis- related complications including rhabdomyolysis 
and/or compartment syndrome.
2.4 | Ocular manifestations of influenza infection
Influenza- associated ocular disease can result from direct conjunctival 
invasion by influenza virus and presents most commonly as a con-
junctivitis although retinopathy, uveal effusion syndrome, and optic 
neuritis have also been reported.173 Avian influenza viruses of the H7 
subtype in particular, with the exception of zoonotic A(H7N9) display 
a prominent ocular tropism compared to other strains of influenza. 
The human conjunctiva expresses the alpha 2- 3 sialic acid residue 
which is preferentially recognized by avian influenza viruses but lacks 
the alpha- 2,6 sialic acid residue that is classically recognized by human 
influenza viruses.174 During an outbreak of avian A(H7N7) influenza in 
the Netherlands, 91% (75/82) of patients presented with conjunctivi-
tis alone and 6% (5/82) had both conjunctivitis and influenza- like ill-
ness.175,176 In British Columbia and Mexico, during outbreaks of highly 
pathogenic avian A(H7N3) infection in poultry, two patients in each 
country were diagnosed with infection after presenting with con-
junctivitis.177,178 In a study of 194 individuals who were actively in-
volved in the culling of infected poultry during the A(H7N7) outbreak 
in the Netherlands, oseltamivir prophylaxis significantly reduced the 
risk of infection per farm visit from 0.145 (95% CI 0.078- 0.233) to 
0.031 (95% CI 0.008- 0.073), suggesting that oseltamivir may have 
efficacy against influenza- associated conjunctivitis.179 Similar results 
were found in murine ocular challenge models in which oseltamivir 
was shown to reduce A(H7N7) and A(H7N3) viral replication in both 
ocular and respiratory tissue.180
Conjunctivitis has also been reported in association with the 
A(H1N1)pdm09 virus.174 In a study of 89 patients with H1N1 infec-
tion, 58 (65%) presented with conjunctivitis, 7 patients (8%) presented 
with uveal effusion syndrome—a unilateral red painful eye associated 
with severe visual loss—and another 3 (3%) presented with optic 
neuritis.173 Both the uveal effusion syndrome and the optic neuritis 
responded to treatment with corticosteroids. More severe ocular man-
ifestations have been reported in association with influenza A(H1N1)
pdm09 infection—two cases of acute retinitis and a case of bleeding 
follicular conjunctivitis.181-183 All three patients recovered their vision 
although one did have persistently impaired color perception. In the 
patient with bleeding follicular conjunctivitis, viral RNA was detected 
by RT- PCR in the affected eye and in one of the retinitis cases, the 
patient  had vitreous antibodies to A(H1N1).
The ophthalmologic complications of influenza are reported vari-
ably and may be strain- specific based on the evidence reviewed. 
However, understanding of these complications is likely limited by 
under- recognition and under- reporting.
2.5 | Renal complications of influenza
Influenza infection can also affect renal function through a number of 
complications including acute kidney injury (AKI), acute glomerulone-
phritis, minimal change disease, and acute tubulointerstitial nephritis 
(ATN).
2.5.1 | Acute kidney injury (AKI)
Observational studies suggest the incidence of influenza- associated 
AKI ranges from 18% to 66% in patients cared for in an ICU set-
ting.184-186 The degree of renal failure can be quite severe, as 8%- 22% 
of patients ultimately require RRT during their hospitalization.187 The 
direct role of influenza vs critical illness in general as the etiology of 
AKI remains unclear, as this rate is similar to RRT utilization among 
critically ill patients without influenza. Risk factors for the development 
of AKI include obesity, presence of chronic kidney disease prior to ill-
ness, older age, and increased severity of illness at admission as deter-
mined by various scoring systems including the Acute Physiology and 
Chronic Health Evaluation II (APACHE II) and Sequential Organ Failure 
Assessment (SOFA).188,189 Additionally, the association between AKI 
and mortality in influenza illness is conflicting, although analysis of 
the largest prospective cohort of A(H1N1)pdm09- infected patients 
suggests that only severe AKI, category III by the Acute Kidney Injury 
Network (AKIN), is independently associated with mortality.186
The underlying pathogenic mechanism of renal injury in influenza 
infection is likely multifactorial. Aside from rhabdomyolysis- mediated 
kidney injury, possible mechanisms include decreased renal perfusion 
secondary to hypovolemia or the vasodilatory state of sepsis fre-
quently associated with severe influenza infection, potentially leading 
to an acute tubular necrosis (ATN). One study of autopsy findings in 
five A(H1N1)pdm09 cases found evidence of ATN in all patients.190 
Similarly, in a study of 21 patients who died with A(H1N1)pdm09 
infection in Brazil, all patients demonstrated mild- to- moderate ATN; 
four of those patients also had myoglobin pigment in the tubules con-
sistent with rhabdomyolysis, and a fifth had evidence of thrombotic 
angiopathy.191 Direct viral injury to the kidneys is another postulated 
mechanism of disease, but there is limited evidence to support this. 
Influenza A(H1N1)pdm09 virus has been detected in the cytoplasm 
of glomerular macrophages in the kidneys of 4 of 5 patients in one 
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post- mortem study; however, this may suggest circulating virus or sim-
ply the presence of viral genetic material in macrophages rather than 
direct invasion.190 There is only one report of a patient with evidence 
of viral shedding in urine.192 Renal complications in the setting of in-
fluenza infection, whether an exacerbation of an underlying condition 
or a novel consequence of the infection, remain poorly defined and 
warrant further investigation.
2.6 | Hepatic complications of influenza
Hepatic complications of influenza are rarely reported, yet recent re-
ports suggest that liver injury occurs in the setting of influenza infec-
tion.193-195 In an uncontrolled human challenge model of influenza 
infection, 4 of 15 human subjects experimentally inoculated with in-
fluenza developed elevated blood transaminase levels (greater than 
threefold the upper limit in two subjects).196 Liver injury may be strain- 
specific as a greater proportion of 97 patients with A(H1N1)pdm09 
infection had elevated AST and ALT (25.78% and 26.31%, respectively) 
compared with 86 patients infected with 2008 seasonal influenza 
virus- infected (18.6% and 7.36%, respectively).193 Additionally, his-
topathologic evidence of centrizonal hemorrhagic necrosis was also 
reported in 78% of patients who died following A(H1N1)pdm09 virus 
infection.197,198 However, liver damage may be a marker of disease 
severity as liver function tests including transaminases, bilirubin, and 
GGT were also associated with duration of hospitalization, hypoxia, 
and CRP.193 Similarly, transaminase elevations have been more com-
monly reported in severe cases of influenza including 60% (6/10) of 
patients infected with highly pathogenic avian A(H5N1) and in 66% 
(73/111) of patients with A(H7N9) infection.198,199
Post- mortem study of three fatal cases of A(H1N1)pdm09 virus 
infection demonstrated viral particles in the endothelial cells, sinusoi-
dal epithelial cells, and hepatic macrophages.200 Influenza virus has 
also been isolated and cultured from the liver of a patient that died of 
influenza A infection.201 However, evidence of viral invasion in hepato-
cytes has not been reliably demonstrated. Alternatively, hepatitis may 
develop as the result of collateral damage during a systemic immune 
response against a non- hepatotropic viral infection or in response to 
drugs that are administered during treatment. This was supported in 
a small study of 11 patients infected with avian A(H7N9) virus infec-
tion who demonstrated a significant correlation between AST levels 
and the Th2 cytokines IL- 4 and IL- 9.202 The absence of influenza virus 
antigen in hepatocytes and the correlation between elevated liver 
function tests and systemic markers of inflammation including CRP 
suggests that the underlying pathogenesis of influenza- associated he-
patic disease is likely a result of systemic inflammation.193
Influenza has also been implicated as the trigger for development 
of acute cellular rejection in patients who have undergone orthotopic 
liver transplant. In two liver transplant patients infected with influenza 
A(H1N1)pdm09 virus, both developed acute cellular rejection (ACR) 
immediately following infection and demonstrated a delayed response 
to corticosteroids.203
Liver injury due to influenza infection, possibly secondary to sys-
temic inflammation mediated by viral infection, appears to be present 
in a percentage of cases suggesting that liver enzymes should be mon-
itored closely.
2.7 | Hematologic complications of influenza
Influenza infection is associated with a variety of hematologic com-
plications including thromboembolic disease, thrombotic thrombo-
cytopenic purpura (TTP), hemolytic- uremic syndrome (HUS), and 
hemophagocytic syndrome (HPS).
2.7.1 | Thromboembolic disease
Post- mortem studies of patients who died from influenza infection have 
offered conflicting evidence about the association between influenza 
infection and thromboembolic disease likely due to differences in study 
design. In eight cases of fatal influenza A(H1N1), a higher incidence of 
pulmonary thrombi (75%) was found in comparison with the reported 
frequency in intensive care unit patients at autopsy (5%).204 However, 
in a nested case- control study of patients suspected to have pulmo-
nary embolism (PE), influenza infection was not identified as an inde-
pendent risk factor (adjusted OR .22; 95% CI 0.03- 1.72.205 Similarly, 
a retrospective review of 119 patients admitted with A(H1N1)pdm09 
infection found that only 5.9% (7/119) had clinically significant throm-
botic events, specifically DVT (3/7; 43%), PE (2/7; 29%), MI (2/7; 29%), 
and one aortic thrombus (1/7; 14%).206 However, a large French case- 
control study of 1454 adults found that influenza vaccination correlates 
with a reduced risk of venous thromboembolic disease, including both 
PE and DVT (OR = 0.74, 95% CI 00.57- 0.97).207
2.7.2 | Hemolytic- uremic syndrome (HUS) and 
thrombotic thrombocytopenic purpura (TTP)
Hemolytic- uremic syndrome (HUS) and thrombotic thrombocytopenic 
purpura (TTP), two overlapping thrombotic microangiopathic syndromes 
defined by non- immune- mediated hemolytic anemia, thrombocyto-
penia, AKI, and neurologic abnormalities, have been rarely associated 
with influenza infection in adults. Only four patients with influenza- 
associated HUS or TTP have been described including one case that 
occurred in a renal transplant patient and one patient who had prior TTP 
and experienced a recurrence in the setting of influenza infection.208-211 
It has been postulated that the viral neuraminidase protein unmasks the 
Thomsen- Friedenreich cryptoantigen, which has previously been impli-
cated in atypical HUS.208,212 Alternatively, one patient with influenza- 
associated TTP developed high titer antibodies against ADAMTS13 (a 
disintegrin and metalloproteinase with a thrombospondin type 1 motic, 
member 13), a protein that cleaves von Willebrand factor (vWF) multim-
ers.209 The association between influenza and TTP, however, is based 
on a paucity of case reports and thus remains speculative.
2.7.3 | Hemophagocytic syndrome
Hemophagocytic syndrome (HPS) is a clinical condition characterized 
by activated macrophages and histiocytes leading to secretion of an 
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extraordinary amount of cytokines and an uncontrolled phagocytosis 
of platelets, erythrocytes, and lymphocytes. It is an uncommon condi-
tion thought to be triggered by specific autoimmune conditions, in-
fections, or malignancy. However, the pathologic finding may be more 
common than thought as one post- mortem review of six patients who 
died of influenza A(H5N1) infection all had evidence of hemophago-
cytosis in the bone marrow on autopsy.213 Influenza has also been 
linked to the development of virus- associated hemophagocytic syn-
drome in three case reports.36,41,214 Two of the patients had a prior 
history of an autoimmune condition that has been independently 
linked to HPS including one with systemic lupus erythematous and 
another with rheumatoid arthritis.215 All patients were treated with 
high- dose steroids, and one was treated additionally with IVIG and all 
survived. The association between influenza infection and TTP and 
HPS provides further evidence that in addition to respiratory disease, 
influenza can exacerbate underlying conditions including activating or 
reactivating autoimmune conditions. Early recognition of the hema-
tologic complications of influenza including TTP or HPS in influenza 
infection is critical to initiate specific therapeutic interventions.
2.8 | Endocrine complications of influenza
Patients with diabetes mellitus are considered high risk for severe in-
fluenza illness by the Center for Disease Control as infectious diseases 
are frequently the trigger for diabetic complications including diabetic 
ketoacidosis (DKA) and hyperglycemic hyperosmolar non- ketotic 
coma (HHNK).216 The association with these diabetic complications 
and influenza was first reported in 1970, when 14 of 29 patients 
(48%) admitted to a hospital in Birmingham, England, also had res-
piratory complaints during a local outbreak of influenza.217 Since then, 
there have been at least 4 case reports of DKA or HHNK in the setting 
of diagnosed influenza—3 with influenza A(H1N1) infection and one 
with influenza B.218-220 Of those patients, 3 (75%) had no previous 
history of diabetes and the diagnosis was unmasked in the setting of 
influenza infection. The type of diabetes was not identified in most of 
the case reports except for one patient who had undetectable serum 
C- peptide levels after glucagon administration, suggesting a diagnosis 
of type I diabetes with no endogenous insulin secretion; however, this 
patient also did not have detectable anti- GAD or anti- IA- 2 antibodies, 
the presence of which can be helpful in the diagnosis of late autoim-
mune diabetes in adults.219 The relationship between diabetes and 
influenza infection is also supported by epidemiologic evidence from 
the Netherlands. Using data on national hospitalizations aggregated 
during time periods with increased diagnoses of influenza- like illness 
in 1976 and 1978, patients were significantly more likely to die of 
DKA than compared to periods when influenza- like illness rates were 
at baseline (25.7% vs 14.6%, P < .01).221 This study also noted that the 
number of hospitalizations for DKA increased by 50% in 1978 com-
pared to the two years prior and the year after. Although evidence is 
lacking to support a true association between influenza infection and 
endocrine complication as opposed to an exacerbation of an underly-
ing disease, a high threshold of suspicious should be maintained in 
assessing for complications of HHNK or DKA.
2.9 | Limitations
The quality of the literature presented is limited as this review re-
lies primarily on case reports, case series, and observational stud-
ies. The complications identified are also difficult to address in the 
context of severe systemic influenza infection as it is unclear if they 
are the consequence of the infection itself, systemic illness or shock 
in general, or an exacerbation of an otherwise underlying condition. 
Additionally, publication bias likely exists as a disproportionately 
large amount of the literature comes from the 2009 H1N1 influenza 
pandemic.
3  | CONCLUSIONS
Influenza viruses are global pathogens that infect up to 20% of the 
world population each year and cause significant morbidity and mor-
tality. However, the burden of influenza is largely based on the iden-
tification of well- recognized respiratory- related manifestations. Data 
presented here from an comprehensive literature review suggest 
that extra- pulmonary complications, including influenza- associated 
cardio- and cerebrovascular events, myocarditis, CNS syndromes, 
and rhabdomyolysis, constitute an under- recognized burden of dis-
ease in patients infected with influenza. Influenza- specific prevention 
with vaccines has been shown to reduce the risk of some of these 
complications but further studies are needed. Similarly, early antiviral 
therapy appears to reduce the risk and/or severity of certain compli-
cations. Early recognition of the extra- pulmonary manifestations of 
influenza infection is critical to the initiation of therapeutic interven-
tions and organ- specific supportive care.
ACKNOWLEDGEMENTS
This work was part of an ISARIC project on influenza complica-
tions supported by the Bill and Melinda Gates Foundation and NIH 
K23AI121516 (WF), R03AG045088 (WF), IDSA Young Investigator 
Award (WF), KLS2TR001109 (WF). We thank ISARIC colleagues 
Gail Carson and Sarah Moore for administrative support. WF and 
FH are members of ISARIC.  The funding sources have had no role 
in the design, data collection, analysis or interpretation of this work 
or in the decision to submit for publication. The authors have not 
been paid to write this article by a pharmaceutical company or other 
agency. The corresponding author has had full access to all data in 
the study and has had final responsibility for the decision to submit 
for publication.
CONFLICT OF INTEREST
SS, RH, FH, and WF report no relevant conflicts of interest.
ETHICS COMMITTEE APPROVAL
N/A.
388  |     SELLERS Et aL
REFERENCES
 1. Fischer WA 2nd, Chason KD, Brighton M, Jaspers I. Live attenuated 
influenza vaccine strains elicit a greater innate immune response than 
antigenically- matched seasonal influenza viruses during infection of 
human nasal epithelial cell cultures. Vaccine. 2014;32:1761-1767.
 2. Molinari NA, Ortega-Sanchez IR, Messonnier ML, et al. The annual 
impact of seasonal influenza in the US: measuring disease burden 
and costs. Vaccine. 2007;25:5086-5096.
 3. Monto AS, Whitley RJ. Seasonal and pandemic influenza: a 2007 up-
date on challenges and solutions. Clin Infect Dis. 2008;46:1024-1031.
 4. Fearnley RA, Lines SW, Lewington AJ, Bodenham AR. Influenza 
A- induced rhabdomyolysis and acute kidney injury complicated 
by posterior reversible encephalopathy syndrome. Anaesthesia. 
2011;66:738-742.
 5. Warren-Gash C, Bhaskaran K, Hayward A, et al. Circulating influ-
enza virus, climatic factors, and acute myocardial infarction: a time 
series study in England and Wales and Hong Kong. J Infect Dis. 
2011;203:1710-1718.
 6. Warren-Gash C, Hayward AC, Hemingway H, et al. Influenza in-
fection and risk of acute myocardial infarction in England and 
Wales: a CALIBER self- controlled case series study. J Infect Dis. 
2012;206:1652-1659.
 7. Warren-Gash C, Smeeth L, Hayward AC. Influenza as a trigger for 
acute myocardial infarction or death from cardiovascular disease: a 
systematic review. Lancet Infect Dis. 2009;9:601-610.
 8. Gurfinkel EP. Influenza vaccine pilot study in acute coronary syn-
dromes and planned percutaneous coronary interventions: the 
FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. 
Circulation. 2002;105:2143-2147.
 9. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. 
Association of influenza vaccination and reduced risk of recurrent 
myocardial infarction. Circulation. 2000;102:3039-3045.
 10. Casscells SW, Granger E, Kress AM, Linton A, Madjid M, Cottrell 
L. Use of oseltamivir after influenza infection is associated with 
reduced incidence of recurrent adverse cardiovascular outcomes 
among military health system beneficiaries with prior cardiovascular 
diseases. Circ Cardiovasc Qual Outcomes. 2009;2:108-115.
 11. Kodama M. Influenza Myocarditis. Circ J. 2010;74:2060-2061.
 12. Karjalainen J, Nieminen MS, Heikkilä J. Influenza Al myocarditis in 
conscripts. Acta Medica Scandinavica. 1980;207:27-30.
 13. Paddock CD, Liu L, Denison AM, et al. Myocardial injury and bacte-
rial pneumonia contribute to the pathogenesis of fatal influenza B 
virus infection. J Infect Dis. 2012;205:895-905.
 14. Oseasohn R, Adelson L, Kaji M. Clinicopathologic study of thirty- 
three fatal cases of Asian influenza. N Engl J Med. 1959;260:509-518.
 15. Ukimura A, Izumi T, Matsumori A, Clinical Research Committee on 
M. A National Survey on Myocarditis Associated With the 2009 
Influenza A (H1N1) Pandemic in Japan. Circ J. 2010;74:2193-2199.
 16. Ukimura A, Ooi Y, Kanzaki Y, Inomata T, Izumi T. A national survey 
on myocarditis associated with influenza H1N1pdm2009 in the 
pandemic and postpandemic season in Japan. J Infect Chemother. 
2013;19:426-431.
 17. Iwanaga N, Nakamura S, Fukuda Y, et al. A fatal case of acute myo-
cardial infarction following the improvement of influenza A(H1N1)
pdm2009- related acute myocarditis. Intern Med. 2014;53:2153-2157.
 18. Larsen TR, Kinni V, Zaks J, David S, McCullough PA. A lethal case of influ-
enza and type 5 cardiorenal syndrome. Blood Purif. 2013;36:112-115.
 19. Taremi M, Amoroso A, Nace HL, Gilliam BL. Influenza B- induced 
refractory cardiogenic shock: a case report. BMC Infect Dis. 
2013;13:452.
 20. Dahdouh Z, Roule V, Lognoné T, Sabatier R, Massetti M, Grollier G. 
Atrial septostomy in cardiogenic shock related to H1N1 infection. 
Acute Cardiac Care. 2012;15:7-9.
 21. Barbandi M, Cordero-Reyes A, Orrego CM, Torre-Amione 
G, Seethamraju H, Estep J. A case series of reversible acute 
cardiomyopathy associated with H1N1 influenza infection. Methodist 
DeBakey Cardiovascu J. 2012;8:42.
 22. Tseng G-S, Hsieh C-Y, Hsu C-T, Lin J-C, Chan J-S. Myopericarditis 
and exertional rhabdomyolysis following an influenza A (H3N2) in-
fection. BMC Infect Dis. 2013;13:283.
 23. Babamahmoodi F, Davoodi AR, Ghasemian R, Delavarian L. Report of 
two rare complications of pandemic influenza A (H1N1). J Infect Dev 
Ctries. 2011;6:204-207.
 24. Davoudi AR, Maleki AR, Beykmohammadi AR, Tayebi A. Fulminant 
myopericarditis in an immunocompetent adult due to pan-
demic 2009 (H1N1) influenza A virus infection. Scand J Infect Dis. 
2012;44:470-472.
 25. Adedayo O, Iheonunekwu N, Jefferson D. Acute fulminant myocardi-
tis and the 2009 pandemic influenza A virus (H1N1). West Indian Med 
J. 2011;60:217-219.
 26. Himmel F, Hunold P, Schunkert H, Bode F. Influenza A positive but 
H1N1 negative myocarditis in a patient coming from a high outbreak 
region of new influenza. Cardiol J. 2011;18:441-445.
 27. Haessler S, Paez A, Rothberg M, Higgins T. 2009 pandemic H1N1- 
associated myocarditis in a previously healthy adult. Clin Microbiol 
Infect. 2011;17:572-574.
 28. Cobas M, Abbo L, Santos M, Baccini-Jauregui C, Pham S. Successful 
management of fulminant influenza A subtype H1N1 myocarditis. 
BMJ Case Rep 2010; https://doi.org/10.1136/bcr.02.2010.2763 
[Epub ahead of print].
 29. Takehana H, Inomata T, Kuwao S, et al. Recurrent fulminant viral 
myocarditis with a short clinical course. Circ J. 2003;67:646-648.
 30. Mamas MA, Fraser D, Neyses L. Cardiovascular manifestations asso-
ciated with influenza virus infection. Int J Cardiol. 2008;130:304-309.
 31. McGovern PC, Chambers S, Blumberg EA, et al. Successful explanta-
tion of a ventricular assist device following fulminant influenza type 
A- associated myocarditis. J Heart Lung Transplant. 2002;21:290-293.
 32. Ray CG, Icenogle TB, Minnich LL, Copeland JG, Grogan TM. The use 
of intravenous ribavirin to treat influenza virus- associated acute 
myocarditis. J Infect Dis. 1989;159:829-836.
 33. Yoshimizu N, Tominaga T, Ito T, et al. Repetitive fulminant influenza 
myocarditis requiring the use of circulatory assist devices. Intern 
Med. 2014;53:109-114.
 34. Chiu CW, Yen HH, Chiu CC, Chen YC, Siao FY. Prolonged cardiac 
arrest: successful resuscitation with extracorporeal membrane oxy-
genation. Am J Emerg Med 2013;31:1627. e1625-1626.
 35. Erden I, Erden EÇ, Özhan H, Basar C. Acute myocarditis mimicking 
acute myocardial infarction associated with pandemic 2009 (H1N1) 
influenza A virus. Cardiol J. 2011;18:552-555.
 36. Horai Y, Miyamura T, Takahama S, et al. Influenza virus B- associated 
hemophagocytic syndrome and recurrent pericarditis in a patient with 
systemic lupus erythematosus. Mod Rheumatol. 2010;20:178-182.
 37. Miura M, Asaumi Y, Wada Y, et al. A case of influenza subtype A 
virus- induced fulminant myocarditis: an experience of percutaneous 
cardio- pulmonary support (PCPS) treatment and immunohistochem-
ical analysis. Tohoku J Exp Med. 2001;195:11-19.
 38. Liao YC, Hsieh YC, Chang WC, Huang JL, Ting CT, Wu TJ. Fulminant 
myocarditis in an adult with 2009 pandemic influenza A (H1N1 influ-
enza) infection. J Chin Med Assoc. 2011;74:130-133.
 39. Khouzam RN, Parizianu C, Hafiz AM, Chawla S, Schwartz R. 
Fulminant myocarditis associated with novel H1N1 influenza A. 
Heart Lung. 2011;40:566-568.
 40. Şahin DY, Demir M, Kurtaran B, Usal A. A case of myocarditis mim-
icking acute coronary syndrome associated with H1N1 influenza A 
virus infection. Türk Kardiyol Dern Arş. 2010;38:572-575.
 41. Asai N, Ohkuni Y, Komatsu A, et al. A case of asthma- complicated 
influenza myocarditis. J Infect Chemother. 2011;17:429-432.
 42. Chang H-L, Hsu J-F, Tsai Y-M, Lin S-Y, Kuo H-F, Yang C-J. Acute re-
spiratory distress syndrome and acute myocarditis developed in a 
previously healthy adult with influenza B. BMC Pulm Med. 2016;16:1.
     |  389SELLERS Et aL
 43. Onitsuka H, Imamura T, Miyamoto N, et al. Clinical manifestations 
of influenza a myocarditis during the influenza epidemic of winter 
1998- 1999. J Cardiol. 2001;37:315-324.
 44. Kaji M, Kuno H, Turu T, Sato Y, Oizumi K. Elevated serum myosin 
light chain I in influenza patients. Internal Med. 2001;40:594-597.
 45. Greaves K, Oxford JS, Price CP, Clarke GH, Crake T. The prevalence 
of myocarditis and skeletal muscle injury during acute viral infection 
in adults: measurement of cardiac troponins I and T in 152 patients 
with acute influenza infection. Arch Intern Med. 2003;163:165-168.
 46. Ison MG, Campbell V, Rembold C, Dent J, Hayden FG. Cardiac find-
ings during uncomplicated acute influenza in ambulatory adults. Clin 
Infect Dis. 2005;40:415-422.
 47. Calabrese F, Carturan E, Chimenti C, et al. Overexpression of 
tumor necrosis factor (TNF)alpha and TNFalpha receptor I in 
human viral myocarditis: clinicopathologic correlations. Mod Pathol. 
2004;17:1108-1118.
 48. Davey RT Jr, Lynfield R, Dwyer DE, et al. The association between 
serum biomarkers and disease outcome in influenza A(H1N1)pdm09 
virus infection: results of two international observational cohort 
studies. PLoS ONE. 2013;8:e57121.
 49. Lee N, Wong CK, Chan PK, et al. Cytokine response patterns in se-
vere pandemic 2009 H1N1 and seasonal influenza among hospital-
ized adults. PLoS ONE. 2011;6:e26050.
 50. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human 
influenza A (H5N1) is associated with high viral load and hypercyto-
kinemia. Nat Med. 2006;12:1203-1207.
 51. Hall MW, Geyer SM, Guo C-Y, et al. Innate immune function and 
mortality in critically ill children with influenza: a multicenter study. 
Crit Care Med. 2013;41:224.
 52. Bradley-Stewart A, Jolly L, Adamson W, et al. Cytokine responses in 
patients with mild or severe influenza A (H1N1) pdm09. J Clin Virol. 
2013;58:100-107.
 53. Kumar K, Guirgis M, Zieroth S, et al. Influenza myocarditis and my-
ositis: case presentation and review of the literature. Can J Cardiol. 
2011;27:514-522.
 54. Martin SS, Hollingsworth CL, Norfolk SG, Wolfe CR, Hollingsworth 
JW. Reversible cardiac dysfunction associated with pandemic 2009 
influenza A(H1N1). Chest. 2010;137:1195-1197.
 55. Brown SM, Pittman J, Miller Iii RR, et al. Right and left heart failure in 
severe H1N1 influenza A infection. Eur Respir J. 2011;37:112-118.
 56. Lichenstein R, Magder LS, King RE, King JC Jr. The relation-
ship between influenza outbreaks and acute ischemic heart dis-
ease in Maryland residents over a 7- year period. J Infect Dis. 
2012;206:821-827.
 57. Madjid M, Miller CC, Zarubaev VV, et al. Influenza epidemics and 
acute respiratory disease activity are associated with a surge in 
autopsy- confirmed coronary heart disease death: results from 8 years 
of autopsies in 34,892 subjects. Eur Heart J. 2007;28:1205-1210.
 58. Smeeth L, Thomas SL, Hall AJ, Hubbard R, Farrington P, Vallance P. 
Risk of myocardial infarction and stroke after acute infection or vac-
cination. N Engl J Med. 2004;351:2611-2618.
 59. Ludwig A, Lucero-Obusan C, Schirmer P, Winston C, Holodniy M. 
Acute cardiac injury events </=30 days after laboratory- confirmed 
influenza virus infection among U.S. veterans, 2010–2012. BMC 
Cardiovasc Disord. 2015;15:109.
 60. Corrales-Medina VF, Musher DM, Wells GA, Chirinos JA, Chen L, 
Fine MJ. Cardiac complications in patients with community- acquired 
pneumonia incidence, timing, risk factors, and association with 
short- term mortality. Circulation. 2012;125:773-781.
 61. Gwini SM, Coupland CA, Siriwardena AN. The effect of influenza 
vaccination on risk of acute myocardial infarction: self- controlled 
case- series study. Vaccine. 2011;29:1145-1149.
 62. Ciszewski A, Bilinska ZT, Brydak LB, et al. Influenza vaccination in 
secondary prevention from coronary ischaemic events in coronary 
artery disease: FLUCAD study. Eur Heart J. 2008;29:1350-1358.
 63. Siriwardena AN, Gwini SM, Coupland CA. Influenza vaccination, 
pneumococcal vaccination and risk of acute myocardial infarction: 
matched case- control study. CMAJ. 2010;182:1617-1623.
 64. Jackson LA. Influenza vaccination is not associated with a re-
duction in the risk of recurrent coronary events. Am J Epidemiol. 
2002;156:634-640.
 65. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in 
triggering acute coronary syndromes. Lancet Infect Dis. 2010;10:83-92.
 66. Naghavi M. Influenza infection exerts prominent inflammatory and 
thrombotic effects on the atherosclerotic plaques of apolipoprotein 
E- deficient mice. Circulation. 2003;107:762-768.
 67. Madjid M, Aboshady I, Awan I, Litovsky S, Casscells SW. Influenza 
and cardiovascular disease: is there a causal relationship? Tex Heart 
Inst J. 2004;31:4.
 68. Tse H, To KK, Wen X, et al. Clinical and virological factors associated 
with viremia in pandemic influenza A/H1N1/2009 virus infection. 
PLoS ONE. 2011;6:e22534.
 69. Likos AM, Kelvin DJ, Cameron CM, Rowe T, Kuehnert MJ, Norris PJ. 
Influenza viremia and the potential for blood- borne transmission. 
Transfusion. 2007;47:1080-1088.
 70. Haidari M, Wyde PR, Litovsky S, et al. Influenza virus directly infects, 
inflames, and resides in the arteries of atherosclerotic and normal 
mice. Atherosclerosis. 2010;208:90-96.
 71. Auer J, Leitinger M, Berent R, et al. Influenza A and B IgG seropositiv-
ity and coronary atherosclerosis assessed by angiography. Heart Dis 
(Hagerstown, Md). 2001;4:349-354.
 72. Krummel-McCracken K. Stroke as a complication of H1N1 influenza 
infection: a case study. Crit Care Nurse. 2011;31:e1-e8.
 73. Burad J, Bhakta P, George J, Kiruchennan S. Development of acute 
ischemic stroke in a patient with acute respiratory distress syndrome 
(ARDS) resulting from H1N1 pneumonia. Acta Anaesthesiol Taiwan. 
2012;50:41-45.
 74. Nichol KL, Nordin J, Mullooly J, Lask R, Fillbrandt K, Iwane M. Influenza 
vaccination and reduction in hospitalizations for cardiac disease and 
stroke among the elderly. N Engl J Med. 2003;348:1322-1332.
 75. Hung IF, Leung AY, Chu DW, et al. Prevention of acute myocardial 
infarction and stroke among elderly persons by dual pneumococcal 
and influenza vaccination: a prospective cohort study. Clin Infect Dis. 
2010;51:1007-1016.
 76. Lavallée P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. 
Association between influenza vaccination and reduced risk of brain 
infarction. Stroke. 2002;33:513-518.
 77. Grau AJ, Fischer B, Barth C, Ling P, Lichy C, Buggle F. Influenza 
vaccination is associated with a reduced risk of stroke. Stroke. 
2005;36:1501-1506.
 78. Lavallée PC, Labreuche J, Fox KM, et al. Influenza vaccination and 
cardiovascular risk in patients with recent TIA and stroke. Neurology. 
2014;82:1905-1913.
 79. Madjid M, Curkendall S, Blumentals WA. The influence of oseltamivir 
treatment on the risk of stroke after influenza infection. Cardiology. 
2009;113:98-107.
 80. Goenka A, Michael BD, Ledger E, et al. Neurological manifestations 
of influenza infection in children and adults: results of a National 
British Surveillance Study. Clinical Infect Dis. 2014;58(6):775-84.
 81. Glaser CA, Winter K, DuBray K, et al. A population- based study of 
neurologic manifestations of severe influenza A (H1N1) pdm09 in 
California. Clin Infect Dis. 2012;55:514-520.
 82. Mizuguchi M. Influenza encephalopathy and related neuropsychiat-
ric syndromes. Influenza Other Respir Viruses. 2013;7:67-71.
 83. Steininger C, Popow-Kraupp T, Laferl H, et al. Acute encepha-
lopathy associated with influenza A virus infection. Clin Infect Dis. 
2003;36:567-574.
 84. Gonzalez BE, Brust DG. Novel influenza A (H1N1) presenting as an 
acute febrile encephalopathy in a mother and daughter. Clin Infect 
Dis. 2009;49:1966-1967.
390  |     SELLERS Et aL
 85. Fugate JE, Lam EM, Rabinstein AA, Wijdicks EF. Acute hemorrhagic 
leukoencephalitis and hypoxic brain injury associated with H1N1 in-
fluenza. Arch Neurol. 2010;67:756-758.
 86. Chen Y-C, Lo C-P, Chang T-P. Novel influenza A (H1N1)- associated 
encephalopathy/encephalitis with severe neurological se-
quelae and unique image features—A case report. J Neurol Sci. 
2010;298:110-113.
 87. Akins PT, Belko J, Uyeki TM, Axelrod Y, Lee KK, Silverthorn J. H1N1 
encephalitis with malignant edema and review of neurologic compli-
cations from influenza. Neurocrit Care. 2010;13:396-406.
 88. Pula JH, Issawi A, DeSanto JR, Kattah JC. Cortical vision loss as a 
prominent feature of H1N1 encephalopathy. J Neuroophthalmol. 
2012;32:48-50.
 89. Ishigami A, S-i Kubo, Ikematsu K, et al. An adult autopsy case of 
acute encephalopathy associated with influenza A virus. Leg Med. 
2004;6:252-255.
 90. Simon M, Hernu R, Cour M, Casalegno J-S, Lina B, Argaud L. Fatal 
influenza A (H1N1) pdm09 encephalopathy in immunocompetent 
man. Emerg Infect Dis. 2013;19:1005.
 91. Bartynski WS, Upadhyaya AR, Boardman JF. Posterior reversible en-
cephalopathy syndrome and cerebral vasculopathy associated with 
influenza A infection: report of a case and review of the literature. J 
Comput Assist Tomogr. 2009;33:917-922.
 92. Hayase Y, Tobita K. Probable post- influenza cerebellitis. Intern Med. 
1997;36:747-749.
 93. Ak Ö, Biteker F, Cag Y, et al. Influenza B- associated encephalopathy 
in two adults. J Infect Chemother. 2012;18:961-964.
 94. Santini M, Kutleša M, Zarkovic K, Drazenovic V, Barsic B. Influenza 
A 2009 H1N1 encephalitis in adults with viral RNA in cerebrospinal 
fluid. Scand J Infect Dis. 2012;44:992-996.
 95. Cheng A, Kuo K-H, Yang C-J. Pandemic (H1N1) 2009 encephalitis in 
woman, Taiwan. Emerg Infect Dis. 2011;17:1925.
 96. Cunha BA, Corbett M, Mickail N. Influenza A presenting as viral en-
cephalitis in an adult. Heart Lung. 2012;41:308-309.
 97. Tsai C-K, Lai Y-H, Yang F-C, Chen C-Y, Peng G-S. Clinical and radio-
logic manifestations of H1N1 virus infection associated with neuro-
logical complications: a case report. Neurologist. 2011;17:228-231.
 98. Ito S, Shima S, Ueda A, Kawamura N, Asakura K, Mutoh T. Transient sple-
nial lesion of the corpus callosum in H1N1 influenza virus- associated 
encephalitis/encephalopathy. Intern Med. 2011;50:915-918.
 99. Alakare J, Jurkko R, Kaukonen K-M, et al. Viral encephalitis associ-
ated with pandemic 2009 (H1N1) influenza A. BMJ Case Rep 2010; 
https://doi.org/10.1136/bcr.02.2010.2772 [Epub ahead of print].
 100. Lee N, Wong CK, Chan PK, et al. Acute encephalopathy associated 
with influenza A infection in adults. Emerg Infect Dis. 2010;16:139.
 101. Locuratolo N, Mannarelli D, Colonnese C, et al. Unusual posterior 
reversible encephalopathy syndrome in a case of influenza A/H1N1 
infection. J Neurol Sci. 2012;321:114-116.
 102. Iijima H, Wakasugi K, Ayabe M, Shoji H, Abe T. A case of adult influ-
enza A virus–associated encephalitis: magnetic resonance imaging 
findings. J Neuroimaging. 2002;12:273-275.
 103. Jeganathan N, Fox M, Schneider J, Gurka D, Bleck T. Acute hem-
orrhagic leukoencephalopathy associated with influenza A (H1N1) 
virus. Neurocrit Care. 2013;19:218-221.
 104. Wang J, Stewart E, Dapaah-Afriyie K, Finn A. Mild encephalopathy 
with reversible splenial lesion in a patient with influenza A infec-
tion—first report in an adult patient in the USA. BMJ Case Rep 2015; 
https://doi.org/10.1136/bcr-2015-210197 [Epub ahead of print].
 105. Tomás J, Macário MC, Gaspar E, Santana I. Severe post- influenza 
(H1N1) encephalitis involving pulvinar nuclei in an adult patient. BMJ 
Case Rep 2015; https://doi.org/10.1136/bcr-2015-212667 [Epub 
ahead of print].
 106. Morishima T, Togashi T, Yokota S, et al. Encephalitis and encephalop-
athy associated with an influenza epidemic in Japan. Clin Infect Dis. 
2002;35:512-517.
 107. Fujimoto S, Kobayashi M, Uemura O, et al. PCR on cerebrospinal 
fluid to show influenza- associated acute encephalopathy or enceph-
alitis. Lancet. 1998;352:873-875.
 108. Pabbaraju K, Tellier R, Wong S, et al. Full- genome analysis of avian 
influenza A (H5N1) virus from a human, North America, 2013. Emerg 
Infect Dis. 2014;20:887-891.
 109. de Jong MD, Cam BV, Qui PT, et al. Fatal avian influenza A (H5N1) 
in a child presenting with diarrhea followed by coma. N Engl J Med. 
2005;352:686-691.
 110. Ichiyama T, Morishima T, Isumi H, Matsufuji H, Matsubara T, 
Furukawa S. Analysis of cytokine levels and NF- κB activation in pe-
ripheral blood mononuclear cells in influenza virus- associated en-
cephalopathy. Cytokine. 2004;27:31-37.
 111. J-i Kawada, Kimura H, Ito Y, et al. Systemic cytokine responses in 
patients with influenza- associated encephalopathy. J Infect Dis. 
2003;188:690-698.
 112. Hasegawa S, Matsushige T, Inoue H, Shirabe K, Fukano R, Ichiyama 
T. Serum and cerebrospinal fluid cytokine profile of patients with 
2009 pandemic H1N1 influenza virus- associated encephalopathy. 
Cytokine. 2011;54:167-172.
 113. Hasegawa S, Matsushige T, Inoue H, et al. Serum soluble CD163 lev-
els in patients with influenza- associated encephalopathy. Brain Dev. 
2013;35:626-629.
 114. Shinohara M, Saitoh M, Takanashi J, et al. Carnitine palmitoyl trans-
ferase II polymorphism is associated with multiple syndromes of 
acute encephalopathy with various infectious diseases. Brain Dev. 
2011;33:512-517.
 115. Shinohara M, Saitoh M, Nishizawa D, et al. ADORA2A polymorphism 
predisposes children to encephalopathy with febrile status epilepti-
cus. Neurology. 2013;80:1571-1576.
 116. Neilson DE, Adams MD, Orr CM, et al. Infection- triggered familial or 
recurrent cases of acute necrotizing encephalopathy caused by mu-
tations in a component of the nuclear pore, RANBP2. Am J Human 
Genet. 2009;84:44-51.
 117. Zhang L-K, Chai F, Li H-Y, Xiao G, Guo L. Identification of host pro-
teins involved in Japanese encephalitis virus infection by quantita-
tive proteomics analysis. J Proteome Res. 2013;12:2666-2678.
 118. Ocwieja KE, Brady TL, Ronen K, et al. HIV integration targeting: 
a pathway involving Transportin- 3 and the nuclear pore protein 
RanBP2. PLoS Pathog. 2011;7:e1001313.
 119. Zhang R, Mehla R, Chauhan A. Perturbation of host nuclear mem-
brane component RanBP2 impairs the nuclear import of human im-
munodeficiency virus- 1 preintegration complex (DNA). PLoS ONE. 
2010;5:e15620.
 120. Sivadon-Tardy V, Orlikowski D, Porcher R, et al. Guillain- Barré syn-
drome and influenza virus infection. Clin Infect Dis. 2009;48:48-56.
 121. Kutleša M, Santini M, Krajinović V, Raffanelli D, Baršić B. Acute 
motor axonal neuropathy associated with pandemic H1N1 influenza 
A infection. Neurocrit Care. 2010;13:98-100.
 122. Hara M, Morita A, Ichihara K, et al. Miller Fisher syndrome associated 
with influenza A infection. Intern Med. 2012;51:2621-2623.
 123. Cortese A, Baldanti F, Tavazzi E, et al. Guillain–Barré syndrome as-
sociated with the D222E variant of the 2009 pandemic influenza A 
(H1N1) virus: case report and review of the literature. J Neurol Sci. 
2012;312:173-176.
 124. Wells C, James W, Evans A. Guillain- Barré syndrome and virus of in-
fluenza A (Asian strain): report of two fatal cases during the 1957 
epidemic in Wales. AMA Arch Neurol Psychiatry. 1959;81:699-705.
 125. Tam CC, O’brien SJ, Petersen I, Islam A, Hayward A, Rodrigues LC. 
Guillain- Barré syndrome and preceding infection with campylo-
bacter, influenza and Epstein- Barr virus in the general practice re-
search database. PLoS ONE. 2007;2:e344.
 126. Tam CC, O’Brien SJ, Rodrigues LC. Influenza, Campylobacter and 
Mycoplasma infections, and hospital admissions for Guillain- Barré 
syndrome, England. Emerg Infect Dis. 2006;12:1880.
     |  391SELLERS Et aL
 127. Sivadon-Tardy V, Orlikowski D, Rozenberg F, et al. Guillain- Barré syn-
drome, greater Paris area. Emerg Infect Dis. 2006;12:990.
 128. Stowe J, Andrews N, Wise L, Miller E. Investigation of the tempo-
ral association of Guillain- Barre syndrome with influenza vaccine 
and influenzalike illness using the United Kingdom General Practice 
Research Database. Am J Epidemiol. 2009;169:382-388.
 129. Lehmann HC, Hartung H-P, Kieseier BC, Hughes RA. Guillain- 
Barré syndrome after exposure to influenza virus. Lancet Infect Dis. 
2010;10:643-651.
 130. Kwong JC, Vasa PP, Campitelli MA, et al. Risk of Guillain- Barré 
syndrome after seasonal influenza vaccination and influenza 
health- care encounters: a self- controlled study. Lancet Infect Dis. 
2013;13:769-776.
 131. Lei T, Siu K-L, Kok K-H, et al. Anti- ganglioside antibodies were not 
detected in human subjects infected with or vaccinated against 2009 
pandemic influenza A (H1N1) virus. Vaccine. 2012;30:2605-2610.
 132. Ravaglia S, Ceroni M, Moglia A, Todeschini A, Marchioni E. Post- 
infectious and postvaccinal acute disseminated encephalomyelitis 
occurring in the same patients. J Neurol. 2004;251:1147-1150.
 133. Jun Y, Yu-Guang W, Yun-Liang X, Xian-Ling R, Yu M, Xing-Wang L. A 
(H1N1) influenza pneumonia with acute disseminated encephalomy-
elitis: a case report. Biomed Environ Sci. 2010;23:323-326.
 134. Wang J, Duan S, Zhao J, Zhang L. Acute disseminated encephalo-
myelitis associated with influenza A H1N1 infection. Neurol Sci. 
2011;32:907-909.
 135. Athauda D, Andrews TC, Holmes PA, Howard RS. Multiphasic acute 
disseminated encephalomyelitis (ADEM) following influenza type A 
(swine specific H1N1). J Neurol. 2012;259:775-778.
 136. Chan A, Ng S. Tumefactive acute disseminated encephalomyeli-
tis complicating human swine influenza (H1N1). Hong Kong Med J. 
2014;20:447-450.
 137. Amano H, Miyamoto N, Shimura H, et al. Influenza- associated MOG 
antibody- positive longitudinally extensive transverse myelitis: a case 
report. BMC Neurol. 2014;14:224.
 138. Partinen M, Kornum BR, Plazzi G, Jennum P, Julkunen I, Vaarala O. 
Narcolepsy as an autoimmune disease: the role of H1N1 infection 
and vaccination. Lancet Neurol. 2014;13:600-613.
 139. Han F, Lin L, Warby SC, et al. Narcolepsy onset is seasonal and in-
creased following the 2009 H1N1 pandemic in China. Ann Neurol. 
2011;70:410-417.
 140. Tesoriero C, Codita A, Zhang M-D, et al. H1N1 influenza virus in-
duces narcolepsy- like sleep disruption and targets sleep–wake regu-
latory neurons in mice. Proc Natl Acad Sci USA. 2016;113:E368-E377.
 141. Varma RR, Riedel DR, Komorowski RA, Harrington GJ, Nowak 
TV. Reye’s syndrome in nonpediatric age groups. JAMA. 
1979;242:1373-1375.
 142. Davis LE, Kornfeld M. Influenza A virus and Reye’s syndrome in 
adults. J Neurol Neurosurg Psychiatry. 1980;43:516-521.
 143. Studahl M. Influenza virus and CNS manifestations. J Clin Virol. 
2003;28:225-232.
 144. McCall S, Henry JM, Reid AH, Taubenberger JK. Influenza RNA not 
detected in archival brain tissues from acute encephalitis lethar-
gica cases or in postencephalitic Parkinson cases. J Neuropathol Exp 
Neurol. 2001;60:696-704.
 145. Lo K, Geddes J, Daniels R, Oxford J. Lack of detection of influenza 
genes in archived formalin- fixed, paraffin wax- embedded brain sam-
ples of encephalitis lethargica patients from 1916 to 1920. Virchows 
Arch. 2003;442:591-596.
 146. Dale RC, Church AJ, Surtees RA, et al. Encephalitis lethargica syn-
drome: 20 new cases and evidence of basal ganglia autoimmunity. 
Brain. 2004;127:21-33.
 147. González-Duarte A, Zamora LM, Brito CC, García-Ramos G. 
Hypothalamic abnormalities and Parkinsonism associated with 
H1N1 influenza infection. J Neuroinflammation. 2010;7:47.
 148. Gamboa ET, Wolf A, Yahr MD, et al. Influenza virus antigen in posten-
cephalitic parkinsonism brain: detection by immunofluorescence. 
Arch Neurol. 1974;31:228-232.
 149. Rohn TT, Catlin LW. Immunolocalization of influenza A virus and 
markers of inflammation in the human Parkinson’s disease brain. 
PLoS ONE. 2011;6:e20495.
 150. Toovey S, Jick SS, Meier CR. Parkinson’s disease or Parkinson symp-
toms following seasonal influenza. Influenza Other Respir Viruses. 
2011;5:328-333.
 151. Tanaka T, Takada T, Takagi D, Takeyama N, Kitazawa Y. Acute renal 
failure due rhabdomyolysis associated with echovirus 9 infec-
tion. A case report and review of literature. Jpn J Med. 1989;28: 
237-242.
 152. Singh U, Scheld WM. Infectious etiologies of rhabdomyolysis: three 
case reports and review. Clin Infect Dis. 1996;22:642-649.
 153. Annerstedt M, Herlitz H, Mölne J. Rhabdomyolysis and acute renal 
failure associated with influenza virus type A. Scandinavian J Urol 
Nephrol. 1999;33:260-264.
 154. Unverdi S, Akay H, Ceri M, et al. Acute kidney injury due 
to Rhabdomyolysis in H1N1 influenza infection. Ren Fail. 
2011;33:450-451.
 155. Naderi ASA, Palmer BF. Rhabdomyolysis and acute renal failure 
associated with influenza virus type B infection. Am J Med Sci. 
2006;332:88-89.
 156. Cunningham E, Kohli R, Venuto RC. Influenza- associated myoglobin-
uric renal failure. JAMA. 1979;242:2428-2429.
 157. Wakabayashi Y, Nakano T, Kikuno T, Ohwada T, Kikawada R. Massive 
rhabdomyolysis associated with influenza A infection. Intern Med. 
1994;33:450-453.
 158. Berry L, Braude S. Influenza A infection with rhabdomyolysis and 
acute renal failure–a potentially fatal complication. Postgrad Med J. 
1991;67:389-390.
 159. Foulkes W, Rees J, Sewry C. Influenza A and rhabdomyolysis. J Infect. 
1990;21:303-304.
 160. Yoshino M, Suzuki S, Adachi K, Fukayama M, Inamatsu T. High inci-
dence of acute myositis with type A influenza virus infection in the 
elderly. Intern Med. 2000;39:431-432.
 161. Ayala E, Kagawa FT, Wehner JH, Tam J, Upadhyay D. 
Rhabdomyolysis associated with 2009 influenza A (H1N1). JAMA. 
2009;302:1863-1864.
 162. Oba K, Nishihara A, Okamura K, et al. Two cases of acute myositis 
associated with influenza A virus infection in the elderly. J Nippon 
Med Sch. 2000;67:126-129.
 163. Parikh M, Dolson G, Ramanathan V, Sangsiraprapha W. Novel 
H1N1- associated rhabdomyolysis leading to acute renal failure. Clin 
Microbiol Infect. 2010;16:330-332.
 164. Kessler HA, Trenholme GM, Harris AA, Levin S. Acute myopathy as-
sociated with influenza A/Texas/1/77 infection: isolation of virus 
from a muscle biopsy specimen. JAMA. 1980;243:461-462.
 165. Kaida K, Kamakura K, Masaki T, Okano M, Nagata N, Inoue K. Painful 
small- fibre multifocal mononeuropathy and local myositis following 
influenza B infection. J Neurol Sci. 1997;151:103-106.
 166. Perez-Padilla R, De La Rosa-zamboni D, Ponce de Leon S, et al. 
Pneumonia and respiratory failure from swine- origin influenza A 
(H1N1) in Mexico. N Engl J Med. 2009;361:680-689.
 167. Borgatta B, Perez M, Rello J, et al. Elevation of creatine kinase is as-
sociated with worse outcomes in 2009 pH1N1 influenza A infection. 
Intensive Care Med. 2012;38:1152-1161.
 168. Armstrong C, Miranda A, Hsu K, Gamboa E. Susceptibility of human 
skeletal muscle culture to influenza virus infection: I. Cytopathology 
and immunofluorescence. J Neurol Sci. 1978;35:43-57.
 169. Desdouits M, Munier S, Prevost MC, et al. Productive infection of 
human skeletal muscle cells by pandemic and seasonal influenza 
A(H1N1) viruses. PLoS ONE. 2013;8:e79628.
392  |     SELLERS Et aL
 170. Gamboa E, Eastwood A, Hays A, Maxwell J, Penn A. Isolation of in-
fluenza virus from muscle in myoglobinuric polymyositis. Neurology. 
1979;29:1323-1335.
 171. Agyeman P, Duppenthaler A, Heininger U, Aebi C. Influenza- 
associated myositis in children. Infection. 2004;32:199-203.
 172. Bove KE, Hilton PK, Partin J, Farrell MK. Morphology of acute my-
opathy associated with influenza B infection. Fetal Pediatric Pathol. 
1983;1:51-66.
 173. Mansour DE, El-Shazly AA, Elawamry AI, Ismail AT. Comparison of 
ocular findings in patients with H1N1 influenza infection versus pa-
tients receiving influenza vaccine during a pandemic. Ophthalmic Res. 
2012;48:134-138.
 174. Chan MC, Chan RW, Yu WC, et al. Tropism and innate host responses 
of the 2009 pandemic H1N1 influenza virus in ex vivo and in vitro 
cultures of human conjunctiva and respiratory tract. Am J Pathol. 
2010;176:1828-1840.
 175. Koopmans M, Wilbrink B, Conyn M, et al. Transmission of H7N7 
avian influenza A virus to human beings during a large outbreak 
in commercial poultry farms in the Netherlands. The Lancet. 
2004;363:587-593.
 176. Fouchier RA, Schneeberger PM, Rozendaal FW, et al. Avian influ-
enza A virus (H7N7) associated with human conjunctivitis and a fatal 
case of acute respiratory distress syndrome. Proc Natl Acad Sci USA. 
2004;101:1356-1361.
 177. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian 
influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10:2196.
 178. CfD Control Prevention. Notes from the field: highly pathogenic avian 
influenza A (H7N3) virus infection in two poultry workers–Jalisco, 
Mexico, July 2012. MMWR: Morb Mortal Wkly Rep. 2012;61:726.
 179. te Beest DE, van Boven M, Bos ME, Stegeman A, Koopmans MP. 
Effectiveness of personal protective equipment and oseltamivir pro-
phylaxis during avian influenza A (H7N7) epidemic, the Netherlands, 
2003. Emerg Infect Dis. 2010;16:1562-1568.
 180. Belser JA, Sleeman K, Pearce MB, Katz JM, Gubareva LV, Tumpey 
TM. Oseltamivir inhibits H7 influenza virus replication in mice 
inoculated by the ocular route. Antimicrob Agents Chemother. 
2012;56:1616-1618.
 181. Lopez-Prats MJ, Sanz Marco E, Hidalgo-Mora JJ, Garcia-Delpech 
S, Diaz-Llopis M. Bleeding follicular conjunctivitis due to influenza 
H1N1 virus. J Ophthalmol. 2010;2010:423672.
 182. Rifkin L, Schaal S. H1N1- associated acute retinitis. Ocul Immunol 
Inflamm. 2012;20:230-232.
 183. Fukami S, Wakakura M, Inouye J. Influenza retinitis: association with 
influenza encephalitis. Ophthalmologica. 2005;219:119-121.
 184. Pettilä V, Webb SA, Bailey M, Howe B, Seppelt IM, Bellomo R. Acute 
kidney injury in patients with influenza A (H1N1) 2009. Intensive 
Care Med. 2011;37:763-767.
 185. Nin N, Lorente J, Soto L, et al. Acute kidney injury in critically ill pa-
tients with 2009 influenza A (H1N1) viral pneumonia: an observa-
tional study. Intensive Care Med. 2011;37:768-774.
 186. Martin-Loeches I, Papiol E, Rodriguez A, et al. Acute kidney injury in 
critical ill patients affected by influenza A (H1N1) virus infection. Crit 
Care. 2011;15:R66.
 187. Demirjian SG, Raina R, Bhimraj A, et al. 2009 influenza A infection 
and acute kidney injury: incidence, risk factors, and complications. 
Am J Nephrol. 2011;34:1-8.
 188. Bagshaw SM, Sood MM, Long J, Fowler RA, Adhikari NK. Acute kid-
ney injury among critically ill patients with pandemic H1N1 influenza 
A in Canada: cohort study. BMC Nephrol. 2013;14:123.
 189. Jung JY, Park BH, Hong SB, et al. Acute kidney injury in critically 
ill patients with pandemic influenza A pneumonia 2009 in Korea: a 
multicenter study. J Crit Care. 2011;26:577-585.
 190. Carmona F, Carlotti AP, Ramalho LN, Costa RS, Ramalho FS. 
Evidence of renal infection in fatal cases of 2009 pandemic influenza 
A (H1N1). Am J Clin Pathol. 2011;136:416-423.
 191. Mauad T, Hajjar LA, Callegari GD, et al. Lung pathology in fatal novel 
human influenza A (H1N1) infection. Am J Respir Crit Care Med. 
2010;181:72-79.
 192. Abdulkader RC, Ho YL, de Sousa Santos S, Caires R, Arantes MF, 
Andrade L. Characteristics of acute kidney injury in patients in-
fected with the 2009 influenza A (H1N1) virus. Clin J Am Soc Nephrol. 
2010;5:1916-1921.
 193. Papic N, Pangercic A, Vargovic M, Barsic B, Vince A, Kuzman I. Liver 
involvement during influenza infection: perspective on the 2009 in-
fluenza pandemic. Influenza Other Respir Viruses. 2012;6:e2-e5.
 194. Duchini A, Viernes ME, Nyberg LM, Hendry RM, Pockros PJ. Hepatic 
decompensation in patients with cirrhosis during infection with in-
fluenza A. Arch Intern Med. 2000;160:113-115.
 195. Whitworth JR, Mack CL, O’Connor JA, Narkewicz MR, Mengshol S, 
Sokol RJ. Acute hepatitis and liver failure associated with influenza A 
infection in children. J Pediatr Gastroenterol Nutr. 2006;43:536-538.
 196. Polakos NK, Cornejo JC, Murray DA, et al. Kupffer cell- 
dependent hepatitis occurs during influenza infection. Am J Pathol 
2006;168:1169-1178 ; quiz 1404-1165.
 197. Bal A, Suri V, Mishra B, et al. Pathology and virology findings in 
cases of fatal influenza A H1N1 virus infection in 2009- 2010. 
Histopathology. 2012;60:326-335.
 198. Yuen KY, Chan PKS, Peiris M, et al. Clinical features and rapid viral 
diagnosis of human disease associated with avian influenza A H5N1 
virus. The Lancet. 1998;351:467-471.
 199. Gao H-N, Lu H-Z, Cao B, et al. Clinical findings in 111 cases of influ-
enza A (H7N9) virus infection. N Engl J Med. 2013;368:2277-2285.
 200. Ru YX, Li YC, Zhao Y, et al. Multiple organ invasion by viruses: patho-
logical characteristics in three fatal cases of the 2009 pandemic in-
fluenza A/H1N1. Ultrastruct Pathol. 2011;35:155-161.
 201. Fraňková V, Jirasek A, Tůmová B. Type A influenza: postmortem virus 
isolations from different organs in human lethal cases. Adv Virol. 
1977;53:265-268.
 202. Han J, Zhang N, Zhang P, et al. Th2- type inflammation under con-
ditions of pre- existing chronic disease is associated with liver dam-
age in patients with avian influenza H7N9 virus. Microbes Infect. 
2014;16:672-677.
 203. Stucchi RS, Boin IF, Angerami RN, et al. Correlations between A/
H1N1 influenza and acute cellular rejection in liver transplantation 
patients. Transplant Proc. 2010;42:4184-4186.
 204. Harms PW, Schmidt LA, Smith LB, et al. Autopsy findings in eight pa-
tients with fatal H1N1 influenza. Am J Clin Pathol. 2010;134:27-35.
 205. van Wissen M, Keller TT, Ronkes B, et al. Influenza infection and risk 
of acute pulmonary embolism. Thromb J. 2007;5:16.
 206. Bunce PE, High SM, Nadjafi M, Stanley K, Liles WC, Christian MD. 
Pandemic H1N1 influenza infection and vascular thrombosis. Clin 
Infect Dis. 2011;52:e14-e17.
 207. Zhu T, Carcaillon L, Martinez I, et al. Association of influenza vac-
cination with reduced risk of venous thromboembolism. Thromb 
Haemost. 2009;102:1259-1264.
 208. Rhee H, Song SH, Lee YJ, et al. Pandemic H1N1 influenza A viral 
infection complicated by atypical hemolytic uremic syndrome and 
diffuse alveolar hemorrhage. Clin Exp Nephrol. 2011;15:948-952.
 209. Kosugi N, Tsurutani Y, Isonishi A, Hori Y, Matsumoto M, Fujimura Y. 
Influenza A infection triggers thrombotic thrombocytopenic pur-
pura by producing the anti- ADAMTS13 IgG inhibitor. Intern Med. 
2010;49:689-693.
 210. Wasserstein A, Hill G, Goldfarb S, Goldberg M. Recurrent throm-
botic thrombocytopenic purpura after viral infection: clinical and 
histologic simulation of chronic glomerulonephritis. Arch Intern Med. 
1981;141:685-687.
 211. Asaka M, Ishikawa I, Nakazawa T, Tomosugi N, Yuri T, Suzuki K. 
Hemolytic uremic syndrome associated with influenza A virus infec-
tion in an adult renal allograft recipient: case report and review of the 
literature. Nephron. 2000;84:258-266.
     |  393SELLERS Et aL
 212. Klein P, Bulla M, Newman R, et al. Thomsen Friedenreich antigen in 
hæmolytic- uræmic syndrome. The Lancet. 1977;310:1024-1025.
 213. To K-F, Chan PK, Chan K-F, et al. Pathology of fatal human infec-
tion associated with avian influenza A H5N1 virus. J Med Virol. 
2001;63:242-246.
 214. Ando M, Miyazaki E, Hiroshige S, et al. Virus associated hemophago-
cytic syndrome accompanied by acute respiratory failure caused by 
influenza A (H3N2). Intern Med. 2006;45:1183-1186.
 215. Fukaya S, Yasuda S, Hashimoto T, et al. Clinical features of hae-
mophagocytic syndrome in patients with systemic autoimmune dis-
eases: analysis of 30 cases. Rheumatology. 2008;47:1686-1691.
 216. Harper SA, Bradley JS, Englund JA, et al. Seasonal influenza in 
adults and children—diagnosis, treatment, chemoprophylaxis, 
and institutional outbreak management: clinical practice guide-
lines of the Infectious Diseases Society of America. Clin Infect Dis. 
2009;48:1003-1032.
 217. Watkins P, Soler N, Fitzgerald M, Malins J. Diabetic ketoacidosis 
during the influenza epidemic. Br Med J. 1970;4:89-91.
 218. Krishna S, Sunil K, Prasad RD, Modi K. Precipitation of new onset 
diabetes by H1N1 infection. Indian J Endocrinol Metab. 2012;16:438.
 219. Sano H, Terasaki J, Tsutsumi C, Imagawa A, Hanafusa T. A case of ful-
minant type 1 diabetes mellitus after influenza B infection. Diabetes 
Res Clin Pract. 2008;79:e8-e9.
 220. Moghadami M, Honarvar B, Sabaeian B, et al. H1N1 influenza in-
fection complicated with diabetic ketoacidosis. Arch Iran Med 
2012;15:55.
 221. Bouter KP, Diepersloot RJ, van Romunde LK, et al. Effect of epidemic 
influenza on ketoacidosis, pneumonia and death in diabetes melli-
tus: a hospital register survey of 1976–1979 in The Netherlands. 
Diabetes Res Clin Pract. 1991;12:61-68.
How to cite this article: Sellers SA, Hagan R, Hayden F, 
Fischer WA II. The hidden burden of influenza: A review of the 
extra- pulmonary complications of influenza infection. Influenza 
Other Respi Viruses. 2017;11:372-393. https://doi.org/ 
10.1111/irv.12470
APPENDIX A
Summary of evidence considered by section
Seventy- five articles that considered cardiac complications of influ-
enza infection were included. Forty- five of these papers considered 
influenza- associated myocarditis, including 23 case reports, 7 case 
series, 10 observational studies, 3 observational autopsy studies, and 
2 review articles. Twenty- one manuscripts were reviewed regarding 
the association between ischemic heart disease and influenza, includ-
ing 8 case- control studies, 4 observational studies, 3 time series stud-
ies, 2 randomized control studies, 2 review articles, and 2 animal 
studies. Nine articles regarding stroke in influenza were reviewed, in-
cluding 4 cohort studies, 3 case- control studies, and 2 case reports.
Sixty- nine articles that considered neurologic complications of 
influenza infection were included. Thirty- nine of these papers 
discussed influenza- associated encephalitis and encephalopathy, 
including 20 case reports, 10 observational cohort studies, 5 case 
series, 3 basic science articles, and 1 review. Fifteen manuscripts 
were reviewed regarding the association between Guillain- Barre 
syndrome and influenza, including 4 case reports, 3 case series, 3 
case- control studies, 2 observational cohort studies, 2 time series 
studies, and 1 review article. Three studies were reviewed regarding 
the association between narcolepsy and influenza infection, includ-
ing 1 observational cohort study, 1 review article, and 1 animal 
study. Similarly, three articles were reviewed regarding Reye’s syn-
drome in the setting of influenza including 2 case series and 1 re-
view article. Seven manuscripts discussing the association of 
influenza with encephalitis lethargica and Parkinson’s syndromes, 
including 4 autopsy studies, 1 case- control study, 1 case series, and 
1 case report.
Twenty- four manuscripts were reviewed regarding the association 
between influenza infection and myopathy or rhabdomyolysis. These 
included 14 case reports, 3 case series, 3 observational cohort studies, 
and 4 basic science articles.
Eleven articles were reviewed regarding ocular complications of in-
fluenza infection. Conjunctivitis was the most well- represented compli-
cation in the literature, as there were 2 observational cohort studies, 2 
case- control studies, 3 basic science papers, 1 case series, and 1 case 
report. One of the case- control studies also addressed optic neuritis as 
a complication, and there were three additional case reports regarding 
acute retinitis and bleeding follicular conjunctivitis.
Ten articles were reviewed discussing the association of acute kid-
ney injury in influenza infection, including 6 observational cohort 
studies, three autopsy studies, and one case report. Although the 
quality of the evidence is reasonably strong, the conclusions drawn 
are inconsistent.
Twelve manuscripts regarding hepatic complications in influenza 
infection were reviewed. This included 4 autopsy studies, 4 observa-
tional cohort studies, 3 case series, 1 human virus challenge study, and 
1 case- control study. The quality of the evidence is overall weak to 
moderate and somewhat inconsistent as it remains unclear whether 
liver disease is directly related to influenza infection or whether it is 
simply a marker of severe infection.
Fourteen manuscripts were reviewed regarding hematologic com-
plications of influenza infection. Four articles discussed the role of 
thromboembolic disease, including 2 case- control studies, 1 cohort 
study, and 1 autopsy study. There were five manuscripts reviewed 
concerning HUS/TTP in the setting of influenza, including 4 case re-
ports and 1 review article. As the support was mostly dependent on 
case reports, the evidence is weak. Five articles addressed the link 
between hemophagocytic syndrome and influenza infection including 
4 case reports and 1 autopsy study.
Five manuscripts were reviewed regarding endocrine complications 
of influenza infection, including 2 case reports, 1 case series, 1 cohort 
study, and 1 time series.
